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Friday, 29th September 2006 
Venue: DKFZ Conference Center 
Time Session Location 
08.00 – 08.30 am Registration Foyer 
08.30 – 08.35 am Welcome/Introduction: Volker Arlt Auditorium 
08.35 – 08.45 am Welcome: Prof. Dr. Otmar Wiestler, Chairman and Scientific Director of the 
German Cancer Research Center 
Auditorium 
 Session I 
Chair: Helmut Bartsch (German Cancer Research Center, Germany) 
 
08.45 – 09.30 am - Keynote Lecture - 
Frederick Beland (National Center for Toxicological Research, USA): 
Acrylamide: adducts, mutations, and cancer (O#1) 
Auditorium 
09.30 – 10.00 am Arthur Grollman (State University of New York, USA): Role of aristolochic acid 
in the etiology of endemic nephropathy (O#2) 
Auditorium 
10.00 – 10.30 am Coffee Break Foyer 
 Session II 
Chair: Peter Farmer (Biocentre, University of Leicester, UK) 
 
10.30 – 11.00 am David Phillips (Institute of Cancer Research, UK): Elucidating pathways of 
metabolic activation of carcinogens by quantifying and characterising their DNA 
adducts (O#3) 
Auditorium 
11.00 – 11.25 am Bernadette Schoket (National Institute of Environmental Health, Hungary): 
Immunoassays for the determination of PAH-DNA adducts (O#4) 
Auditorium 
11.25 – 11.50 am Karen Brown (University Leicester, UK): Accelerator mass spectrometry for DNA 
adduct detection (O#5) 
Auditorium 
11.50 – 12.15 pm Lennart Möller (Karolinska Institute, Sweden): DNA-adduct analyses of human 
tissues by the 32P-HPLC method (O#6) 
Auditorium 
12.15 – 01.00 pm Lunch Break Canteen 
01.00 – 01.45 pm Poster Presentation: Session 1 Foyer 
01.45 – 02.30 pm Poster Presentation: Session 2 Foyer 
 Session III 
Chair: David Phillips (Institute of Cancer Research, UK) 
 
02.30 – 02.55 pm Peter Farmer (Biocentre Leicester, UK): Alternative approaches to 32P-
postlabelling for detection of low levels of DNA adducts (O#7) 
Auditorium 
Workshop Programme 
 5Workshop Programme 
02.55 – 03.20 pm  Jagadeesan Nair (German Cancer Research Center, Germany): Novel 32P-
postlabelling method for the determination of adducted deoxynucleosides in human 
body fluids (O#8) 
Auditorium 
03.20 – 03.45 pm Oliver Schmitz (University Wuppertal, Germany): Determination of the DNA 
methylation level with capillary electrophoresis and laser-induced fluorescence 
(O#9) 
Auditorium 
03.45 – 04.15 pm Coffee Break Foyer 
 Session IV 
Chair: Frederik-Jan van Schooten (University of Maastricht, The Netherlands) 
 
04.15 – 04.40 pm Matilde Marques (Technical University of Lisbon, Portugal): Tamoxifen and 
tamoxifen analogues: activation to DNA adducts in vitro and in vivo (O#10) 
Auditorium 
04.40 – 05.05 pm Volker Manfred Arlt (Institute of Cancer Research, UK): The potential use of 
DNA adducts formed by the carcinogenic air pollutant 3-nitrobenzanthrone in 
human biomonitoring (O#11) 
Auditorium 
05.05 – 05.30 pm Marie Stiborova (Charles University Prague, Czech Republik): Cytochrome P450- 
and peroxidase-mediated formation of covalent DNA adducts by an anticancer 
drug ellipticine - a novel mechanism of ellipticine action (O#12) 
Auditorium 
05.30 – 05.55 pm Heinz Schmeiser (German Cancer Research Center, Germany): Molecular basis of 
Aristolochia carcinogenicity (O#13) 
Auditorium 
05.55 – 06.15 pm Coffee Break Foyer 
 Symposium Prof. Manfred Wiessler (65th birthday) 
Chair: Heinz Schmeiser & Eva Frei (German Cancer Research Center, Germany) 
 
06.15 – 07.15 pm Otmar Wiestler (German Cancer Research Center, Germany): Welcome 
Gerd Eisenbrand (University Kaiserslautern, Germany): Highlights of the 
scientific career of Prof. Manfred Wiessler 
Christopher Michejda (National Cancer Institute at Frederick, USA): Replication 
control in tumor cells as a target for DNA-interacting anti-tumor agents (O#14) 
Auditorium 












Saturday, 30th September 2006 
Venue: DKFZ Conference Center 
Time Session Location 
 Session V 
Chair: Bernadette Schoket (National Institute of Environmental Health,Hungary) 
 
08.30 – 08.55 am Panagiotis Georgiadis (National Hellenic Research Foundation, Greece): 
Progress towards the development of high-throughput immunochemical assays 
for DNA damage and repair (O#15) 
Auditorium 
08.55 – 09.20 am Dan Segerbäck (Karolinska Institute, Sweden): 32P-Postlabelling analysis of 
UV-induced pyrimidine dimers from human skin and urine (O#16) 
Auditorium 
09.20 – 09.45 am Hansruedi Glatt (German Institute of Human Nutrition, Germany): Formation 
of DNA adducts in humans and laboratory animals by phytochemicals from 
common vegetables and fruits (O#17) 
Auditorium 
09.45 – 10.15 am Coffee Break Foyer 
 Session VI 
Chair: Soterios Kyrtopoulos (National Hellenic Research Foundation, Greece) 
 
10.15 – 10.45 am Monica Hollstein (German Cancer Research Center, Germany): In vitro cell 
immortalization selects for p53 gene mutations found in human cancers (O#18) 
Auditorium 
10.45 – 11.10 am Albrecht Seidel (Biochemical Institute for Environmental Carcinogens, 
Germany): Determination of urinary PAH metabolites as a non-invasive human 
biomonitoring method (O#19) 
Auditorium 
11.10 – 11.35 am Jan Topinka (Institute of Experimental Medicine AS, Czech Republic): Use of 
DNA adduct analysis to study mechanism of drug genotoxicity - example 
cyproterone acetate (CPA) (O#20) 
Auditorium 
11.35 – 12.00 pm Erwin Eder (University of Würzburg, Germany): Early markers in the 
development of colorectal tumours in the rat: DNA adducts compared with 
isoprostanes, histological and morphological alterations in the early stage 
(O#21) 
Auditorium 
12.00 – 01.00 pm Coffee Break & Lunch Snacks Foyer 
 Session VII 
Chair: Oliver Schmitz (University of Wuppertal, Germany) 
 
01.00 – 01.25 pm Roger Godschalk (University of Maastricht, The Netherlands): The use of DNA 
adducts in surrogate tissues: pitfalls and opportunities (O#22) 
Auditorium 
01.25 – 01.50 pm Marco Peluso (Tuscany Cancer Institute, Italy): DNA adducts and lung cancer 
risk in a case-control study nested in the EPIC investigation (O#23) 
Auditorium 
01.50 – 02.15 pm Elmar Richter (University of Munich, Germany): Sources of adducts releasing 
4-hydroxy-1-(3-pyridyl)-1-butanone (HPB) from DNA and haemoglobin in 
humans (O#24) 
Auditorium 
02.15 – 02.40 pm Wolfgang Pfau (GAB-Consulting, Germany): Dietary DNA adducts: Auditorium 
Workshop Programme 
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heterocyclic amines and pesticides (O#25) 
02.40 – 03.05 pm Werner Lutz (University of Würzburg, Germany): Correlation of DNA adducts 
with other endpoints of genotoxicity in mouse lymphoma cells treated with 
methyl methanesulfonate (O#26) 
Auditorium 
03.05 – 03.10 pm Closing Remarks: Heinz Schmeiser Auditorium 















































































































































































































                                                                                                                          
The Societies (EEMS and GUM) 
The European Environmental Mutagen Society (EEMS) and 
the German speaking section GUM (Gesellschaft für 
Umweltmutationsforschung), home to scientists active in 
fundamental and applied research in genetic toxicology, 
mutagenesis and carcinogenesis, are announcing their joint  
meeting for 9-13 September 2007 in Basel.  
   
The Subject:  The dose makes the poison –  
what makes a mutagen? 
Basel is one of the founding locations of the European 
chemical and pharmaceutical industry and its name figures 
prominently in the history of  medical therapy and toxicology. 
Theophrastus Bombastus von Hohenheim (Paracelsus) 
taught in the city during the 16th century. The first part of the 
conference theme, which is assigned to him, laid the basis for 
toxicology as we know it today. Hence, it is only consistent 
that one topic of the EEMS 2007 meeting will be devoted to 
revisiting the dose-response concept and risk assessment in 
our science. In addition, Friedrich Miescher, the discoverer of 
nucleic acids has spent his scientific life in Basel, further 





Basel, the largest city of northwestern Switzerland, is located 
in the tri-national region of Switzerland, France and Germany. 
This unique location inspires a multilingual environment and 
multicultural flair. The international ambience is supported by 
the fact that Basel is home to the global headquarters of two 
of the worlds largest pharmaceutical companies, Novartis and 
Hoffmann-LaRoche.  
The industrial background in Basel is matched by the basic 
research of the University and its various institutes. Founded 
in 1460, the University is the oldest in Switzerland and one of 
the most influential. The brand new Pharmazentrum at the 
Biozentrum of the Basel University right in the city centre is 
well known for its expertise and excellent scientific 
contributions in toxicology and will serve as the venue for the 
EEMS 2007, providing up-to-date conference facilities.  
 
 
„Dislocated metaphase chromosomes“ 
 
Access to Basel 
Basel/Mulhouse airport is located just outside the city 
(connecting European cities by various discount carriers), 
assuring a convenient journey to Basel. Zurich airport is one 
hour away by train/car.  Hotels of various categories will allow 
you to find accommodation for any budget. 
Scientific Programme 
The main organizers of the EEMS-2007 will be the 
genotoxicity groups of Novartis and Hoffmann-La Roche. 
Aside of the fundamental research basis of the EEMS, an 
emphasis of the meeting will be on applied research and 











Main Subjects (tentative) 
 Dose response 
 Risk assessment – risk perception – risk 
communication 
 Stem cell toxicology / genotoxicity 
 Nanomaterial toxicology / genotoxicity 
 Image analysis – high content screening 
 Structure-activity prediction 
 DNA adducts and carcinogenesis 
 Mutations in cancer genes 
 Biologicals and genotoxicity/tumourigenicity 
 Biomonitoring and risk assessment 
 DNA repair  and cancer risk 
 Genotoxicity and non-cancer diseases 
 Genetic engineering 































































                                                                                                                        
Programme Committee (tentative) 











Peter Kasper  
Stephan Kirchner  
David Kirkland  
Micheline Kirsch-Volders  
 
Jos Kleinjans  
Lisbeth Knudsen  
Hans Jörg Martus  
Lutz Müller  
Wolfgang Muster 
Ulla Plappert-Helbig 
Andreas Rothfuss  
Peter Sagelsdorff  
Alain Sarasin  
Bernadette Schoket  
Helga Stopper  
Willi Suter  
Krzysztof Szyfter  





Basel with its tri-national situation is located at the heart of 
Europe. The “Münster“ in the medieval city centre and many 
museums are attractions on their own. Switzerland with its 
many world famous sites and views such as the UNESCO 
World cultural heritage city of Berne (www.berninfo.com), 
Lucerne (www.luzern.org) or the Eiger-Jungfrau mountain 
region (www.about.ch/cantons/bern/eiger_moench_jungfrau) 
are only less than two hours away by car or train. Also the 
french winery region of Alsace (www.tourisme-alsace.com) 
or the popular Black Forest (www.schwarzwald-sued.de) in 
Germany are within close vicinity and invite you for a tour 
before or after the conference. The social programme will 






Local Organizing Committee 
Hans Jörg Martus (Hansjoerg.Martus@novartis.com) 
Novartis Pharma AG; Bldg. MUT-2881.5.43 
CH-4002 Basel, Switzerland 
Tel: +41 (0)61 3241569 
Lutz Müller (Lutz.Mueller@roche.com) 
F. Hoffmann-La Roche Ltd., PRBN-T, Bldg. 73/311b 
CH-4070 Basel, Switzerland 
Tel: +41 (0)61 6882733 
These colleagues are your primary contact partners for 
further information about the conference.  
Pablo Tosin (pablo.tosin@bluewin.ch) of TOSIN Productions 
Luftmattstrasse 17; CH-4052 Basel;  
Tel: +41 (0)79 334 87 26  is the local conference organizer 
Commercial Exhibitions 
Space is available for commercial exihibions and companies 
active in the area of genetic toxicology; in silico, in vitro and 
in vivo testing services; cellular imaging; etc. are encouraged 
to present their business at this meeting.  
For further information contact : 
Dr. Wilfried Frieauff (Wilfried.Frieauff@novartis.com) 
Novartis Pharma AG, Bldg. MUT-2881.5.07 
CH-4002 Basel, Switzerland 
Tel: +41 (0)61 3241595 
 
Weblinks 






























































































































































Acrylamide: adducts, mutations, and cancer 
 
F.A. Beland 
National Center for Toxicological Research, Division of Biochemical Toxicology, Jefferson, AR, USA. 
 
Acrylamide, a water-soluble α,β-unsaturated amide, is a high-volume industrial chemical, a component of cigarette 
smoke, and more recently, has been detected as a contaminant in baked and fried starchy foods, including French fries, 
potato chips, and bread. Acrylamide is carcinogenic in experimental animals; however, the mechanism of tumor 
induction is controversial, with both genotoxic and non-genotoxic pathways being proposed.  Acrylamide is oxidized to 
the epoxide glycidamide, an electrophilic metabolite that could contribute to a genotoxic mechanism of tumorigenicity.  
Glycidamide reacts with DNA to form several DNA adducts including N7-(2-carbamoyl-2-hydroxyethyl)deoxy-
guanosine and N3-(2-carbamoyl-2-hydroxyethyl)deoxyadenosine, which readily depurinate to give N7-(2-carbamoyl-2-
hydroxyethyl)guanine (N7-GA-Gua) and N3-(2-carbamoyl-2-hydroxyethyl)adenine (N3-GA-Ade). In order to 
investigate the contribution of glycidamide to the carcinogenicity of acrylamide, we have compared the extent of DNA 
adduct formation by acrylamide and glycidamide in experimental animals using HPLC coupled with electrospray 
ionization tandem mass spectrometry.  The administration of a single dose of acrylamide or glycidamide to adult rats 
produced N7-GA-Gua and N3-GA-Ade in DNA from all tissues examined, with glycidamide giving adduct levels 160-
560% higher than acrylamide. N7-GA-Gua and N3-GA-Ade were also detected in DNA from adult mice treated in a 
similar manner, but the adduct levels from glycidamide were only 16-150% higher than those observed with acrylamide, 
which reflects the more efficient conversion of acrylamide to glycidamide in adult mice compared to adult rats. In infant 
mice, glycidamide gave much higher adduct levels than acrylamide, and also induced micronuclei in reticulocytes and 
normochromatic erythrocytes and an increase in the Hprt mutant frequency in spleen lymphocytes. These data suggest 
that the carcinogenicity of acrylamide is mediated through its metabolism to glycidamide. Bioassays are currently being 
conducted to test this. 
 
O#2 
Role of aristolochic acid in the etiology of endemic nephropathy  
 
A.P. Grollman1, S. Shibutani1, and B. Jelakovic2  
1. State University of New York at Stony Brook, Department of Pharmacological Sciences, Laboratory of Chemical 
Biology, Stony Brook, New York;  2. University of Zagreb School of Medicine, Department of Medicine, Zagreb, 
Croatia.  
 
Balkan endemic nephropathy (EN) affects men and women living in rural areas of Croatia, Bulgaria, Romania, Serbia 
and Bosnia. The disease, first recognized 50 years ago, is characterized by its invariable progression to renal failure and 
a strong association with upper urothelial cancer. Significant epidemiologic features of EN include its occurrence only 
in certain rural villages where only certain households are affected; a familial, but not inherited, pattern of disease; and 
overt manifestation in adults over 30 years of age. Based on clinical and pathologic findings in patients with aristolochic 
acid (AA) nephropathy, the results of a pilot epidemiologic study (Croat Med J 46: 116 (2005)), and detection of dA-
AA and dG-AA adducts in the renal cortex of patients with EN, we have resurrected an earlier hypothesis that chronic 
dietary ingestion of aristolochic acid, in the form of home-baked bread prepared with contaminated wheat grain, is 
responsible for EN and its associated urothelial cancer. An alternative hypothesis invokes exposure of susceptible 
individuals to a mycotoxin, ochratoxin A (OTA). Data has been published in favor of (Chem Res Toxicol, 18:1091 
(2005) and against (Chem Res Toxicol 18: 1082 (2005) the central proposal that OTA is genotoxic to humans and 
animals. In contrast, the genotoxicity and mutagenicity of aristolochic acid in humans and animals have been 
demonstrated clearly (Mutagenesis, 17: 265 (2002)). In this lecture, the strengths and pitfalls of using DNA adducts as 
biomarkers of disease will be illustrated by a critical evaluation of ochratoxin-induced DNA damage and presentation of 
new data suggesting the role of aristolochic acid in the etiology of EN. By resolving apparent discrepancies in these 
scientific reports, public health measures can be recommended for eradicating an environmental agent responsible for a 
devastating renal disease for which 100,000 people are currently at risk.  
 








Institute of Cancer Research, Section of Molecular Carcinogenesis, Sutton, Surrey SM2 5NG UK. 
 
Detecting DNA adduct formation by carcinogens and deducing how they were formed has proved to be an effective 
strategy for elucidating their mechanisms of metabolic activation. Initially such studies were done using radiolabelled 
compounds and comparing the chromatographic properties of the radiolabelled adducts with those formed in vitro by 
synthesised reactive derivatives of the carcinogen. More recently 32P-postlabelling analysis has largely replaced the 
need for radiolabelled test chemicals. The pathways of activation of carcinogens can now be readily deduced from the 
patterns and extent of adduct formation of putative metabolites and reactive derivatives of the parent compound. 
Examples from our lab include several PAHs, 3-nitrobenzanthrone and tamoxifen. Manipulating the enzyme 
functionality of the activating system and then observing the effect on DNA adduct formation is an effective way of 
determining which enzymes activate, or detoxify, carcinogens. Thus tamoxifen activation has been shown to be 
mediated by sulfotransferase(s) and not acetyltransferases. However, studies on benzo[a]pyrene-DNA adduct formation 
have revealed an apparent paradox, whereby CYP1A1 activity appears to be essential for metabolic activation in vitro, 
but in some in vivo situations, DNA adduct formation increases when this enzyme is inhibited or absent. 
 
O#4 
Immunoassays for the determination of PAH-DNA adducts 
 
B. Schoket 
Department of Molecular Environmental Epidemiology, National Institute of Environmental Health, József Fodor 
National Center for Public Health, Budapest, Hungary. 
 
Molecular dosimetry of human genotoxic exposure and determination of carcinogen-DNA adducts have advanced 
substantially during the last two decades. After 32P-postlabelling, immunoassay is the second most sensitive method for 
the detection of polycyclic aromatic hydrocarbon (PAH)-DNA adducts in experimental samples and human tissues. (±)-
7β,8α-dihydroxy-9α,10α-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene-7,8-diol 9,10-epoxide (BPDE)-DNA immuno-
assays, utilising monoclonal antibody or polyclonal antisera elicited against DNA modified with BPDE, recognise not 
only benzo[a]pyrene (BP)-derived but chemically related PAH-DNA adducts as well due to cross-reactivity of the 
antibody. Competitive enzyme-linked immunosorbent assay (ELISA), the first immunoassay used with human samples, 
is less sensitive than dissociation-enhanced lanthanide fluoroimmunoassay (DELFIA), which has time-resolved 
measurement of the long-lived fluorescent signal and short-lived background fluorescence. Chemiluminescence 
immunoassay (CIA), the most sensitive and stable immunoassay, has the lowest percentage of samples below the 
detection limit, a detection limit of 1.5 BPdG adducts/109 nucleotides with 20 µg DNA/microtiter plate well and a high 
signal-to-noise ratio. The Automated Cellular Imaging System (ACIS) provides a novel approach to semi-quantification 
of PAH-DNA adducts in nuclei of tissues stained immunohistochemically with the BPDE-DNA antiserum.  
Approximation of the DNA adduct levels is obtained by comparison with a standard curve consisting of cultured human 
cells exposed to increasing concentrations of BPDE and assayed by both CIA and ACIS.  DELFIA and CIA have been 
applied in the validation of a BPDE-DNA adduct standard, and PAH-DNA immunoassays have contributed to human 
biomonitoring of occupational, medicinal, environmental and tobacco-smoke PAH exposures.  
 
Acknowledgements: Valuable discussions with Dr. Miriam C. Poirier, National Cancer Institute, Bethesda, MD, USA, 
are highly appreciated. The author of this abstract is partner of ECNIS (Environmental Cancer Risk, Nutrition and 
Individual Susceptibility), a  network of excellence operating within the European Union 6th Framework Program, 
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O#5 
Accelerator mass spectrometry for DNA adduct detection 
 
K. Brown 
Cancer Biomarkers and Prevention Group, Department of Cancer Studies and Molecular Medicine, University of 
Leicester, Leicester, LE1 7RH, UK. 
 
Accelerator mass spectrometry (AMS), a technique most commonly known for radiocarbon dating, is becoming 
increasingly popular in biomedical research and development where it can quantify the isotopes 14C and 3H down to 
attomole (10-18) levels in biological samples. The exquisite sensitivity of AMS makes it one of the most sensitive 
methods for quantifying DNA and protein adduct formation by a 14C-labelled chemical, capable of measuring as little as 
1-10 adducts/1012 nucleotides. AMS has been used to illustrate DNA adduct formation in vivo by carcinogens such as 
PhIP, MeIQx and benzo[a]pyrene, following administration of dietary or environmentally relevant doses to humans. We 
have employed AMS to elucidate mechanisms of tamoxifen carcinogenesis and have identified CYP3A4 as the human 
CYP form that catalyses the metabolic activation and covalent binding of tamoxifen to DNA. We have also shown that 
tamoxifen is capable of binding at extremely low levels to DNA in the uterus of women administered a single 14C-
labelled therapeutic dose prior to hysterectomy. Importantly, AMS has been used by others to demonstrate a lack of 
DNA adduct formation by the chemicals TCDD and ochratoxin, supporting a non-genotoxic mechanism for these 
carcinogens. New 14C-postlabelling approaches, which exploit the sensitivity of AMS for detecting DNA damage 
generated in vivo, without the need to administer a radioisotope labelled compound are currently under development. 
We have reported an assay for the detection of O6-methyldeoxyguanosine by chemical postlabelling of HPLC-isolated 
adducts using 14C-acetic anhydride, which can attain a theoretical limit of detection of 79amol. The availability of 
smaller AMS instruments dedicated to the analysis of biological samples, particularly those with on-line HPLC 
capability, together with advances in sample preparation methods should lead to a more widespread use of this 
technology in biomedical research, including the field of genetic toxicology. 
 
O#6 
DNA-adduct analyses of human tissues by the 32P-HPLC method 
  
L. Möller, M. Zeisig, E. Nagy, T. Seidal, and L. Eriksson 
Karolinska Institutet, Department of Biosciences and Nutrition, Novum, SE-141 57 Huddinge, Sweden. 
 
In the analysis of human tissues it is a need for a high-resolution chromatographic system to enable separation of 
individual DNA-adducts and clusters of DNA-adducts. The 32P-post-labeling method is very sensitive in detecting 
DNA-adducts enabling analysis down to 1 DNA-adduct/109 normal nucleotides. When combining the post-labeling 
method with direct injection into the HPLC system with on-line detection of 32P the high sensitivity can be combined 
with a high resolution. The 32P-HPLC system can further be modified by changing flow and composition of solvents to 
optimize resolution and/or to optimize capacity. By changing the chromatographic properties a high resolution can be 
obtained between stereoisomers of a DNA-adduct forming metabolite. If a certain DNA-adduct or DNA-adduct cluster 
is the target, the analytical system can be modified to increase the number of samples to be analyzed with a factor of 
five. It is most common to analyze white blood cells for DNA-adducts due to accessibility. Such analyses can detect 
changes in the environment (air pollution) such as season, with high levels during the winter season and a 
recovery/repair during the summer period. White blood cells can also be treated in vitro (after monthly in vivo 
collections from the same individuals) by mutagens showing an induction of certain parts of the CYP 450 system with a 
consequence of a higher level of DNA-adducts, in this case during summer time. Another approach is to analyze DNA-
adducts in solid tissues. One example was when human placenta was analyzed from different regions representing 
"control" vs. polluted areas. With blind samples it was possible to characterize the mothers as being from "control" or 
polluted areas. Biopsies of solid tissues were applied in a study of colon cancer. In all cases normal colonic mucosa was 
sampled, but the patients represented three groups, healthy, polyp- and cancer-patients. Most DNA-adducts were similar, 
but two declined from healthy, over polyp to cancer patients. One DNA-adduct was only observed in colon cancer 
patients. In autopsy samples the DNA-adduct pattern has a great variability. First there are great differences between 
people living in the same area. One example with liver tissue from people that lived in the same area showed a variation 
of 180 times in the total DNA-adduct level. Analyses of different tissues from one person can show a great variation, 
where lung is lower probably due to the high turnover of the lung cells. Other tissues like the brain and heart can on the 
other hand be high in DNA-adducts, suggesting a possible link to other diseases than cancer (i.e. ageing of tissues). 
 




Alternative approaches to 32P-postlabelling for detection of low levels of DNA adducts 
 
P.B. Farmer and R. Singh 
Cancer Biomarkers and Prevention Group, Biocentre, University of Leicester, University Road, Leicester, LE1 7RH, 
UK. 
 
The methodology for the determination of DNA adducts is capable of determination of unlabelled adducts at levels 
down to 1 adduct per 1010 nucleotides. The main procedures used to date are based on immunoassay, HPLC with 
fluorescence or electrochemical detection, 32P-postlabelling or mass spectrometry.  Another method of detection that is 
currently being explored is laser induced fluorescence, which also yields very high sensitivity. If the adduct carries a 
14C or a 3H label, accelerator mass spectrometry provides the highest sensitivity of all adduct determination techniques 
(1 adduct per 1012 nucleotides).  All of these techniques hold particular advantages and disadvantages, but 32P-
postlabelling is at present the method which is applied to the largest range of adducts.  Recently the sensitivity of mass 
spectrometric techniques, which have the ability to give enhanced structural information compared to 32P-postlabelling, 
has improved to a level approaching that obtained by 32P-postlabelling. Thus liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) using electrospray ionisation and selected reaction monitoring has been used to determine a 
number of adducted deoxynucleosides in enzymic hydrolysates of adducted DNA. For example we have recently 
developed a method to determine the benzo[a]pyrene adduct with the N2-position of 2’-deoxyguanosine, using LC-
MS/MS and a stable isotope labelled internal standard, with a sensitivity of 3 adducts per 108 nucleotides (Singh et al, 
Chem. Res Toxicol., 2006, 19, 868-878). Adducts with 2’-deoxyguanosine appear to have a common collision-induced 
MS/MS fragmentation, loss of m/z 116, corresponding to loss of the deoxyribose residue, which gives rise to the 
possibility of developing a screening system for these adducts. The first example of the use of such a technique (termed 
‘adductomics’) has recently been published by Kanaly et al, Antiox. Redox Signal. 8, 993-1001, 2006.  
 
O#8 
Novel 32P-postlabelling method for the determination of adducted deoxynucleosides in human body fluids 
 
J. Nair 
Division of Toxicology and Cancer Risk Factors, German Cancer Research Center, Im Neuenheiner Feld 280, 
Heidelberg, Germany.  
 
Non-invasive detection methods such as urinalysis will expedite studies in humans aimed to elucidate etiopathological 
factors that cause DNA damage. Etheno-DNA adducts are generated from exogenous carcinogens such as vinyl 
chloride, urethane and also from, oxidative stress/ lipid peroxidation product such as trans-4-hydroxy-2-nonenal. We 
and others have established that 1,N6-ethenodeoxyadenosine (εdA) and 3,N4-ethenodeoxycytidine () are present in 
human urine which could be explored as biomarkers for monitoring whole body oxidative stress.  Here, we report a new 
ultrasensitive 32P-postlabeling/TLC method for the analysis of εdC as deoxynucleoside in human urine. The urine 
samples were purified and enriched on a solid-phase silica C-18 column followed by a semi-preparative reverse phase 
HPLC. The purified sample was labelled with a multisubstrate deoxyribonucleoside kinase from Drosophila 
melanogaster (Dm-dNK) in presence of 5’-bromo-2’-deoxyuridine (BrdU) as internal standard. The absolute sensitivity 
of the method was 0.1 fmol εdC detectable in 500 µl of human urine. The analysis of human urine samples from 15 
healthy volunteers revealed a mean εdC level of 2.49 ± 1.76 (SD) fmol/µmol creatinine (range 0.66-6.42). By our non-
invasive method, εdC in human urine could be explored as a biomarker for oxidative stress-related human diseases. 
Currently the method is being applied to the analysis of εdC in human pancreatic juice. [Ref: X. Sun, A. Karlsson, H. 
Bartsch, and J. Nair, Biomarkers 11, 329-340, 2006] 
 
O#9 
Determination of the DNA methylation level with capillary electrophoresis-laser-induced fluorescence (CE-LIF) 
 
O.J. Schmitz 
Department of Analytical Chemistry, University of Wuppertal, Wuppertal, Germany.  
 
The epigenetic code, i.e. the methylation of cytosines, various histone modifications and DNA-binding proteins, is, 
unlike the genetic code, always being rewritten and erased. Epigenetic mistakes are involved not only in mutations in 
the genotype, but also in the development of abnormalities, cancer and other diseases. With a capillary electrophoretic 
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method we have described previously, the genomic methylation level can be determined very exactly. For coping with 
the increased quantity of samples in an adequate time, we present here a sample preparation that eliminates, after the 
derivatisation reaction, the surplus of fluorescence marker and the carbodiimide that is used for the coupling. With this 
method, sequences of up to 120 measurements can be carried out, which increased the sample throughput from 75 to 
250 analyses per week. In addition the development of a new detector system is presented. The new detector unit is 
based on an Ar-ion laser with a spectrometer and a CCD camera, and the limit of detection of the fluorescence label 
BODIPY was determined as 5 pM. This allows us to determine DNA modification, after BODIPY labeling, at a 





Tamoxifen and tamoxifen analogues: activation to DNA adducts in vitro and in vivo 
 
M.M Marques 
Centro de Química Estrutural, Instituto Superior Técnico, Lisbon, Portugal. 
 
The antiestrogen tamoxifen is used as an adjuvant chemotherapeutic agent for the treatment of breast cancer and as a 
chemopreventive agent in high risk women. Despite being beneficial in this context, tamoxifen increases the risk of 
endometrial cancer in women. The mechanisms for the induction of endometrial tumors by tamoxifen are presently 
uncertain, although both genotoxic and hormonal pathways could be involved. Tamoxifen is hepatocarcinogenic in rats, 
and this has been associated with DNA adduct formation by reactive derivatives of the metabolites α-hydroxytamoxifen 
and α-hydroxy-N-desmethyltamoxifen. However, the occurrence of tamoxifen-DNA adducts in the human endometrium 
remains controversial although a number of analytical methodologies, including 32P-postlabeling and mass spectrometry, 
have been used to address the issue. Assuming a genotoxic pathway to tamoxifen-induced endometrial carcinogenesis, 
tamoxifen analogues less susceptible to metabolic activation to derivatives capable of reacting with DNA could be 
advantageous in the therapeutic setting. Two such analogues are toremifene, an effective chemotherapeutic agent in 
postmenopausal women with advanced breast cancer, and GW5638, which is being considered as an adjuvant 
chemotherapeutic agent. We have synthesized the α−hydroxy and α−sulfoxy derivatives of toremifene and GW5638, 
characterized the DNA adducts that are formed in vitro, and investigated whether or not these adducts are formed in 
vivo. α−Sulfoxytoremifene gave two major DNA adducts in vitro. 32P-Postlabeling analyses of liver DNA from rats 
administered α-hydroxytoremifene indicated the same two DNA adducts; nonetheless, the 32P-postlabeling data 
confirmed a much lower in vivo genotoxicity of toremifene and α-hydroxytoremifene, as compared to tamoxifen. Two 
DNA adducts were also obtained in vitro from reaction of α-sulfoxyGW5638 with DNA; however, hepatic DNA 
adducts were not detected by 32P-postlabeling following administration of GW5638 to rats. Potential implications 








Section of Molecular Carcinogenesis, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK. 
 
Epidemiological studies have shown that exposure to diesel exhaust and urban air pollution is associated with an 
increased risk of lung cancer. 3-Nitrobenzanthrone (3-NBA) is an extremely potent mutagen and suspected human 
carcinogen identified in diesel exhaust and ambient air particulate matter. The main metabolite of 3-NBA, 3-
aminobenzanthrone (3-ABA), was found in the urine of salt mine workers occupationally exposed to diesel emissions, 
indicating that human exposure to 3-NBA due to diesel emissions can be significant and is detectable. There is clear 
evidence that 3-NBA is a genotoxic mutagen forming DNA adducts after metabolic activation through simple reduction 
of the nitro group. Several human enzymes have been shown to activate 3-NBA and its metabolites in vitro and in cells 
leading to the formation of purine adducts at the C8 and N2 position of guanine and at the C8 and N6 position of 
adenine. The predominant DNA adducts in vivo, 2-(2́-deoxyguanosin-N2-yl)-3-aminobenzanthrone (dG-N2-ABA) and 
N-(2́-deoxyguanosin-8-yl)-3-aminobenzanthrone (dG-C8-N-ABA) are also the most persistent adducts in target tissue 
in rodents, and are most probably responsible for the induction of GC→TA transversion mutations observed in vivo. It 
is concluded that these adducts not only represent premutagenic lesions in DNA but are of primary importance for the 
initiation of the carcinogenic process and subsequent tumour formation in target tissue. Indeed, 3-NBA is carcinogenic 
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in rats after intratracheal instillation, inducing mainly squamous cell carcinoma in lung. Because of its widespread 
environmental presence, 3-NBA may represent not only an occupational health hazard but also a hazard for larger 
sections of the general population. For an accurate risk assessment more epidemiological studies on 3-NBA-exposed 




Cytochrome P450- and peroxidase-mediated formation of covalent DNA adducts by an anticancer drug 
ellipticine - a novel mechanism of ellipticine action 
 
M. Stiborová1, H.H. Schmeiser2, M. Wiessler2, and Eva Frei2 
1. Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, 128 40 Prague 2, Czech 
Republic; 2. Division of Molecular Toxicology, German Cancer Research Center, D-69120 Heidelberg, Germany. 
Ellipticine is an antineoplastic agent exhibiting the multimodal mechanism of its action. While the prevalent 
mechanisms of ellipticine antitumor, mutagenic and cytotoxic activities were suggested to be intercalation into DNA 
and inhibition of DNA topoisomerase II activity, based on data found by us, ellipticine should be considered a drug, 
whose pharmacological efficiency and/or genotoxic side effects are dependent also on its cytochrome P450 (CYP)- 
and/or peroxidase-mediated activation in target tissues. We demonstrate a new mode of ellipticine action, formation of 
covalent DNA adducts mediated by its oxidation with CYPs and peroxidases. Using 32P-postlabeling assay we found 
such DNA-adducts in vitro, in V79 cells transfected with human CYP1A1, 1A2 and 3A4, human breast 
adenocarcinoma MCF-7 cells, human leukemia HL-60 and CCRF-CEM and neuroblastoma cell lines and in vivo in rats 
exposed to ellipticine. We report the molecular mechanism of ellipticine oxidation by CYPs and identifies human and 
rat CYPs responsible for ellipticine metabolic activation and detoxication. We also present a role of peroxidases (i.e. 
myeloperoxidase, cyclooxygenases, lactoperoxidase) in ellipticine oxidation leading to ellipticine-DNA adducts. The 9-
hydroxy- and 7-hydroxyellipticine metabolites formed by CYPs and the major product of ellipticine oxidation by 
peroxidases, the dimer, in which the two ellipticine residues are connected through nitrogen N6 in the pyrrole ring of 
one of the ellipticine moieties and carbon C9 of the other ellipticine, are the detoxication metabolites. 13-Hydroxy- and 
12-hydroxyellipticine, produced by ellipticine oxidation with CYPs, the latter one formed also spontaneously from 
another metabolite, ellipticine N2-oxide, are metabolites responsible for formation of two ellipticine-derived 
deoxyguanosine adducts in DNA. The results shown here allow us to propose species, two carbenium ions, ellipticine-
13-ylium and ellipticine-12-ylium, as reactive species generating two major DNA adducts seen in vivo in rats treated 
with ellipticine. The study forms the basis to further predict the susceptibility of human cancers to ellipticine. Supported 




Molecular basis of ARISTOLOCHIA carcinogenicity 
 
H.H. Schmeiser 
Division of Molecular Toxicology, German Cancer Research Centre, Heidelberg, Germany. 
 
The use of a herbal weight-loss product, containing Aristolochia species has been associated with the development of a 
novel nephropathy, and urothelial cancer. The observed nephropathy and urothelial carcinoma has been traced to the 
ingestion of aristolochic acid (AA) and is now called aristolochic acid nephropathy (AAN). The major components of 
the plant extract AA, aristolochic acid I (AAI) and aristolochic acid II (AAII), are genotoxic mutagens forming DNA 
adducts after metabolic activation catalysed by several human enzymes. The activating metabolism has been elucidated 
and is consistent with the formation of a cyclic nitreniumion with delocalised charge leading to the preferential 
formation of purine adducts bound to the exocyclic amino groups of deoxyadenosine and deoxyguanosine. The 
predominantly formed DNA adduct 7-(deoxyadenosin-N6-yl)aristolactam I (dA-AAI) in vivo was detected in AAN 
patients unambiguously proofing the exposure to AA. dA-AAI the most persistent adduct in target tissue and therefore 
detectable in urothelial tissue from AAN patients 10 years after they stopped taking the weight-loss regimen is a 
mutagenic lesion leading to AT→TA transversions in vitro. This transversion mutation is found in high frequency in 
codon 61 of the H-ras oncogene in tumours of rodents induced by AAI, suggesting that dA-AAI might be the critical 
lesion in the carcinogenic process in rodents. Interestingly, in one AAN patient available for analysis the identical 
AT→TA transversion mutation was found in the p53 gene in urothelial tumour cells. AA is a powerful nephrotoxic and 
carcinogenic substance with an extremely short latency period not only in animals but also in humans. In particular the 
highly similar metabolic pathway of activation and resultant DNA adducts of AA which are detectable by the 32P-
postlabeling method, allows the extrapolation of carcinogenesis data from laboratory animals to the human situation. 
These findings draw one of the strongest links yet between use of a herbal product and cancer in humans. Therefore, all 
botanical-containing products known or suspected of containing AA should be banned from the market worldwide. 
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Symposium Prof. Manfred Wiessler 
 
O#14 
Replication control in tumor cells as a target for DNA-interacting anti-tumor agents 
 
C.J. Michejda1, T. Kosakowska-Cholody1, C.J. Meyer2, M.J. Wick3, S.F. Stinson1, A.P. Monks1, W.M. Cholody1, 
H. Haripraksha1, and B.I. Carr4  
1. NCI-Frederick, Frederick, MD, USA; 2. Reata Pharmaceutical, Inc., Dallas, TX, USA; 3. Institute for Drug 
Research, San Antonio, TX, USA; 4. University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 
  
HKH40A, 2-(3-{4-[3-(8-methoxy-6-oxo-6H-2,10b-diaza-aceanthrylen-5-ylamino)-propyl]-piperazin-1-yl}-propyl)-5-
nitro-benzo[de]isoquinoline-1,3-dione, and WMC79, the des-methoxy analog of HKH40A, are synthetic agents with 
potent activity against gastrointestinal and hematopoietic tumors. However, HKH40A has superior pharmacokinetic 
characteristics and significantly better in vivo activity. Cell-based assays have consistently shown that HKH40A is 3-5 
times more active than WMC79, especially in tumors with mutated p53. Both compounds kill p53(+/+) tumors by up-
regulation of the p53 apoptotic cascade, which appears to be induced by transcriptional down-regulation of 
ribonucleotide reductase (RNR) that controls dNTP pools and the cyclin-dependent kinases Cdc6 and Cdc7 that regulate 
replication. Up-regulation of RNR has recently been identified as a key factor in gemcitabine resistance. HKH40A 
causes dramatic down-regulation of these genes as well as those of the MCM family, which are important targets of 
Cdc7. Downregulation of the kinases in p53(-/-) tumor cells puts them into replicative arrest, and premature entry into 
S-phase that results in genomic instability, aberrant mitosis and cell death. Normal cells appear to be less affected by the 
drug because premature progression through the cell cycle is prevented by checkpoint controls, which are frequently 
disrupted in tumor cells. Consequently, HKH40A has a good therapeutic index.  HKH40A is potently active (curative) 
in an orthotopic model of liver cancer (JM-1) in Fisher 344 rats when administered IP.  However, HKH40A and 
WMC79 are most active in vivo against xenografted tumors when injected IV although WMC79 is significantly less 
stable in circulation, probably because of more rapid metabolic clearance in the liver. HKH40A showed good activity in 
HCT116 colon cancer xenografts in nu/nu mice (TGI 65%) and in BxPC-3 pancreatic cancer xenograft (TGI 71%). The 
combination of HKH40A and gemcitabine was tested in MIA PaCa-2 pancreatic cancer in nu/nu mice and produced 





Progress towards the development of high-throughput immunochemical assays for DNA damage and repair 
 
P. Georgiadis 
Institute of Biological Research and Biotechnology, National Hellenic Research Foundation, Athens, Greece. 
 
The need for sensitive, high-throughput and economical methods to assay DNA damage and repair is widely recognized, 
especially in view of prospects of large-scale molecular epidemiology studies. Immunochemical methods hold a 
potential for satisfying these criteria, while at the same time providing the moderate-to-high specificity required for 
chemical-specific biomarkers of exposure. In this context we are making a systematic effort to develop such 
methodologies, and will present a short report of progress achieved. 
a) The measurement of the activity of the repair enzyme O6-methylguanine-DNA methyltransferase (MGMT) is 
important both for studies of chemical and environmental carcinogenesis by methylating carcinogens (eg nitrosamines) 
and for studies of the susceptibility of cancer patients to the therapeutic effects of methylating cytostatic drugs. The 
commonly used method for assaying MGMT activity in tissue or cell extracts is based on the use of a [3H]-methylated 
DNA substrate and the multi-step assay of the transfer of [3H]-methyl groups to the protein. Current experience 
indicates difficulties in the availability of the abovementioned substrate, while the throughput of the assay is limited by 
the need for multiple steps including centrifugation, precipitate dissolution and radiocounting. We have exploited the 
fact that O6-benzylguanine (BG) can serve as an efficient substrate for MGMT to develop a sensitive and rapid ELISA 
method for the assay of MGMT activity: Extracts are incubated with BG tagged with biotin, and the resulting MGMT-
BG-biotin complex is immobilized on anti-MGMT-coated microtiter plates, followed by quantitation using 
streptavidine-conjugated horseradish peroxidase and a chemiluminescence-producing substrate. The method is highly 
sensitive (LOD: 0.5 fmol MGMT protein versus 3 fmol of the old method), has an extremely high dynamic range (0.5-
500 fmol versus 3-20 fmol of the old method), is relatively inexpensive and can be easily automated.  
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b) Immunochemical assays of various types (RIA, competitive or non-competitive ELISA) have been reported for 
various types of DNA adducts. We are currently making an effort to develop a new approach to the immunochemical 
assay of DNA damage which, if successful, holds the potential not only of high sensitivity and throughput, but also of 
multi-adduct analysis on the same DNA sample. Our approach, still under development, is based on the use, in an 
ELISA set up, of immobilised anti-adduct antibodies to extract adduct-containing DNA fragments from bulk DNA, 
followed by their detection and quantitation using anti-DNA antibodies. The high ratio of normal nucleotides (providing 
epitopes for interaction with the latter) to adducts on each adduct-containing fragment provides a possibility for strong 
signal enhancement. Furthermore, the DNA not bound to the first anti-adduct antibody can be collected and used for the 
assay of additional types of adducts using a similar setup. 
 
O#16 
32P-Postlabelling analysis of UV induced pyrimidine dimers from human skin and urine 
 
D. Segerbäck and K. Hemminki 
Department of Biosciences and Nutrition, Karolinska Institute, Novum, Huddinge, Sweden. 
 
Ultraviolet irradiation (UV) is considered to be a major causative factor in human skin cancer. The major products 
induced by UV in DNA are dipyrimidinic lesions, which are likely to be important in the pathogenesis of skin cancer. In 
our studies of human volunteers exposed to solar simulated UV radiation we excised skin biopsies after exposure and 
analysed UV dimers in DNA by a sensitive 32P-postlabelling assay. The obtained data showed that high levels of dimers 
are formed in human skin in situ after just a single dose of solar simulated UV light corresponding to what will be 
obtained during one hour in summer time Stockholm. Furthermore, those lesions were repaired, and with a mixed time 
kinetics, i.e. an initial fast removal followed by a slower phase. Large inter individual differences were observed, both 
in formation and repair of DNA damage. Use of sun screens was shown to be highly protective against formation of UV 
dimers. Case control studies with basal cell carcinoma patients indicated a reduced capacity to remove UV damage 
among the cancer cases. More recently we developed a postlabelling assay for detection of UV dimers present in urine 
as a result of DNA repair. This assay has the advantage that it is non-invasive and can thus be applied also to studies in 
children. So far carried out studies showed that the amount of dimer excreted into urine was correlated to the applied 
UV dose and that high levels of such lesions were also found in children following a couple of hours of sun exposure. In 
conclusion, our studies have shown that DNA damage by UV light can be analysed in humans following doses that 
everyone will receive just by spending a few hours outside and that there are inter individual differences that may have 
implications for who will develop cancer. 
 
O#17 
Formation of DNA adducts in humans and laboratory animals by phytochemicals from common vegetables and 
fruits 
 
H.R. Glatt and C. Baasanjav 
German Institute of Human Nutrition, Potsdam-Rehbrücke, Department of Nutritional Toxicology, 14558 Nuthetal, 
Germany. 
 
Plants have to defend themselves against infecting microorganisms and herbivores animals, at least in certain stage of 
the vegetation cycle. We hypothesized that reactive chemicals could provide universal protection, in contrast to stable 
molecules interacting with specific structures of the enemy. These reactive species would have to be released directly 
after damage to the plant or after activation by common enzymes in enemies such as glycosidases. We observed that 
adducts are formed with the endogenous DNA in homogenates of various raw plants in a time-dependent manner. In 
general, the adducts were not formed when plants were cooked prior to homogenization.  The patterns of adducts were 
similar within genetically closely related plants (e.g. Brassicaceae) but different between phylogenetically remote 
plants (e.g. broccoli, nutmeg, peer). Such homogenates or appropriate extracts were mutagenic in bacterial and 
mammalian target cells in culture, with formation of the same patterns of adducts as in the plant homogenates. Human 
volunteers have chewed such plants. Formation of plant-characteristics DNA adducts was detected in oral cells and, at 
lower levels, in blood cells. In one case, we also had the opportunity to analyse colon biopsies (with a negative result in 
this case). In rats accustomed to the consumption of raw broccoli, a treatment-associated DNA adduct was detected in 
liver that co-migrated with   the major adduct in Broccoli homogenate. The study shows that plants can produce natural 
genotoxicants that may lead to damage in consumers. Damage is not seen when food is prepared in an appropriate way. 
It may be envisaged to searched for varieties that produce less genotoxicants.  
This work is financially supported by BMBF (grant PTJ-BIO/0313053A). 
 
 




In vitro cell immortalization selects for p53 gene mutations found in human cancers 
 
M. Reinbold1, T. Nedelko1, H.H. Schmeiser2, and M. Hollstein1 
1. Division of Genetic Alterations in Carcinogenesis, and 2. Division of Molecular Toxicology, German Cancer 
Research Center, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany. 
 
The ability to induce point mutations in the p53 tumor suppressor gene in its normal genomic context, and then select 
mammalian cells carrying the mutations would be useful for testing hypotheses on the origins of p53 mutations in 
human tumors. To design such an approach, we first introduced human p53 DNA binding domain sequences into the 
endogenous murine p53 locus by gene-targeting, and then generated mice harbouring the humanized p53 knock-in 
configuration in both alleles.  This mouse (Hupki, for human p53 knock-in) is phenotypically p53 wild-type. Embryonic 
fibroblasts from this strain,  like embryonic fibroblasts (MEFs) from mice with unperturbed endogenous mouse p53 
wild-type alleles, senesce in vitro after a number of population doublings, but occasionally escape growth arrest, 
proliferate,  and become established as immortalized cell lines. Bypass of senescence in mouse cells typically occurs as 
a consequence of a molecular event that disrupts p53/ARF function, such as a mutation in the p53 DNA binding domain 
(DBD). Overcoming senescence thus serves as a ‘natural’ method to select for p53 mutant mouse cells. Indeed, DNA 
from immortalized Hupki embryonic fibroblast cultures exposed during early passage to the mutagenic pro-carcinogens 
benzo(a)pyrene (BaP) and aristolochic acid I (AAI) reveal the presence of  homozygous or heterozygous p53 DBD 
mutations. The predominant class of mutation in BaP-immortalized lines is G to T, whereas in AAI-treated cells, most 
mutations are A to T transversions, with strong evidence of strand-bias. BaP mutations are at codons frequently mutated 
in human cancers, and the base substitutions are characteristic for the major pre-mutagenic DNA adducts these 
chemicals form. To explore the effects on mutation and immortalization of the two common human p53 variants at 
codon 72 encoding arginine or proline we generated a second  knock-in mouse encoding the proline variant of p53, but 






Determination of urinary excreted PAH metabolites as a non-invasive human biomonitoring method 
 
A. Seidel, G. Dettbarn, A. John, and J. Jacob 
Biochemical Institute for Environmental Carcinogens Prof. Dr. Gernot Grimmer-Foundation, Grosshansdorf, 
Germany. 
 
Polycyclic aromatic hydrocarbons (PAH) are widespread occurring environmental contaminants some of which are well 
known human carcinogens. Apart from personal smoking habits, the general population is exposed to low level of PAH 
in ambient air particulate matter and contaminated food. Biological monitoring of PAH metabolites in human urine is 
the method of choice to assess the internal dose of an individual as it reflects all different uptake routes (inhalation, 
ingestion, and dermal resorption). Urinary excreted phenols of naphthalene, pyrene and phenanthrene are selected to be 
used as biomarkers of an exposure to PAH because metabolites of higher moleculat weight PAH, such as 
benzo[a]pyrene, are urinary excreted only in very small amounts. Among the phenols 1-hydroxypyrene (1-OHP) is the 
most frequently determined PAH metabolite and in Germany and USA references values for this biomarker have been 
calculated for the general population from environmental surveys performed in these countries. During the last years 
several analytical procedures have been developed based on HPLC and GC/MS methodologies allowing to determine 1-
OHP and an additional battery of phenols from naphthalene, phenanthrene and other PAH. Recently, analytical 
procedures have been developed to determine more polar PAH metabolites excreted in urine. The levels of the new 
biomarkers 1,6- and 1,8-dihydroxypyrene, formed from 1-OHP by further oxidation, have been determined in the 
general population. Notably, the ratio of 1-OHP and dihydroxypyrenes varies greatly depending on the exposure level. 
Other examples are phenanthrene diols and the highly polar phenanthrene tetrol. The latter biomarker is excreted in 
similar amounts as the phenanthrols and reflects the metabolic activation pathway of carcinogenic PAH to bay region 
diol epoxides. The various types of phenanthrene metabolites have been proposed to be used in future studies for 





 20Oral Presentations 
O#20 
Use of DNA adduct analysis to study mechanisms of drug genotoxicity - example cyproterone acetate (CPA)  
 
J. Topinka1,2, U. Andrae2, L.R. Schwarz2, S. Werner2, and T. Wolff2 
1. Institute of Experimental Medicine AS CR, Prague, Czech Republic; 2. GSF-Institute of Toxicology, Neuherberg, 
Germany. 
 
The mechanistic study was performed in rat hepatocytes on the synthetic gestagen and antiandrogen cyproterone acetate 
(CPA), an active component of several drugs widely used in human therapy for many years as an active component of 
oral contraceptives (Diane 35) or treatment of hypersexual behavior and several other indications (Androcur). CPA was 
originally regarded as a typical tumor promoter causing in high doses liver tumors in rats. In the basic battery of tests of 
genotoxicity, CPA exhibited no indication of any mutagenic potential. However, by using of rat hepatocytes we have 
clearly demonstrated that CPA, as a first synthetic steroid, induced formation of high levels of DNA adducts [Topinka 
et al., Carcinogenesis 14 (1993) 423-427]. These DNA adduct levels were much higher than those induced by structural 
analogues of CPA [Topinka et al., Carcinogenesis 16 (1995) 1483-1487]. The CPA induced DNA adducts were 
persistent and accumulating [Werner et al., Carcinogenesis 16 (1995) 2369-2372]. We have also shown that CPA is an 
integral part of DNA adducts detected in hepatocytes treated with CPA [Topinka et al., Carcinogenesis 17 (1996) 167-
169] and the activation pathway of CPA to DNA reactive metabolites via the action of  keto-reductases and hydroxy-
steroid sulfo-transferases has been demonstrated [Schwarz et al., Advances in Experimental Biology, 387 (1996) 243-
251]. Hepatic CPA-DNA adducts are fixed in the liver as point mutations [Topinka et al., Mutation Res. 550 (2004) 89-
99] and we have shown that DNA adduct formation  is not the only prerequisite of mutagenic effect of CPA [Topinka et 
al., Mutation Res. 550 (2004) 101-108]. Non-linearity of dose response curve of mutagenic effect in vivo in target tissue 
of carcinogenesis and the existence of no-effect level of CPA proved in agreement with epidemiologic studies that 
contraceptive dose of CPA does not represent any significant risk. 
 
O#21 
Early markers in the development of colorectal tumours in the rat: DNA adducts compared with isoprostanes, 
histological and morphological alterations in the early stage 
 
E. Eder1, E. Biskup1, P. Wanek1, and J. Müller2 
1. Department of Toxicology, and 2. Institute of Pathology, University of Würzburg, Würzburg, Germany. 
 
Dextrane sulfate induced colitis leads to increased formation of polyps and colon cancer via inflammation, oxidative 
stress and lipid peroxidation. Anti-inflammatory substances, anti-oxidative compounds, other secondary plant 
ingredients or selenium substitution in case of selenium lack in nutrition can act as chemopreventives in colorectal 
cancer. Neither the detailed mechanisms of such chemopreventives are entirely known, nor are the single states of colon 
carcinogenesis by oxidative stress and the course from inflammation to precarcinogenic lesions and final colo-rectal 
carcinoma investigated in detail. In the study the impacts of chemopreventives were investigated on each single step in 
the development of colon cancer on a morphological and molecular biological base. Early markers are prostaglandin 
F2α  for inflammation, 8-iso prostaglandin F2α for oxidative stress, E-cadherin, beta-catenin, Ki67, rate of apoptosis and 
1,N2-propanodeoxyguanosine adducts of the lipid peroxidation product 4-hydroxy-2-nonenal (HNE-dGp) as early 
markers for DNA damage, mutation and cancer initiation. These parameters are compared with morphological changes 
like crypt architecture, preneoplastic aberrations and late markers like colon polyps and carcinoma. We established a 
special 32P-postlabelling technique for HNE-dGp with a detection sensitivity of 2-3 adducts / 109 nucleotides and found 
background adducts levels in human and animal tissues. Adduct levels were increased after induction of lipid 
peroxidation. The HNE-dGp adducts are promutagenic DNA lesions leading to mutations in tumour suppressor genes 
and proto-oncogenes, are not repaired by base excision repair and are highly specific for 4-hydroxynonenal because 
they still contain the structural moiety of 4-hydroxy-2-nonenal. After 16, 28 days and 6 month we found increased 
levels of the early markers in rats induced with dextrane sulfate and fed with vitamin E and selenium deficient diet. We 
expect polyps 12 months after start of the application of dextrane sulfate and of carcinoma after 24 months in the animal 









The use of DNA adducts in surrogate tissues: pitfalls and opportunities 
 
R.W.L. Godschalk 
Department of Health Risk Analysis and Toxicology, University of Maastricht, Maastricht, The Netherlands. 
 
Carcinogen-DNA adducts can be applied to assess the biologically effective dose and to identify individuals at high 
cancer risk. However, practical and ethical considerations limit the types of tissues available for DNA adduct analysis. 
Therefore, DNA adducts have predominantly been studied in easily available white blood cells (WBC) or in cells 
obtained by broncho-alveolar lavages (BAL). WBC consist of 3 subpopulations: monocytes, lymphocytes and 
granulocytes, which differ in their relative abundance in blood (ca. 5-10%, 20-40% and 50-75%, respectively). DNA 
adduct levels after in vitro and in vivo exposure to polycyclic aromatic hydrocarbons were higher in monocytes and 
lymphocytes than in granulocytes. Furthermore, DNA adduct levels were more persistent in lymphocytes than in short-
lived monocytes or granulocytes, which makes the number of adducts that are detectable in total WBC after a given 
amount of time uncertain. On the other hand, these differences in adduct persistency give the opportunity to get 
information about the time since exposure has ended by comparing DNA adduct levels in lymphocytes with those in 
monocytes. Overall, assessment of DNA adducts in total WBC instead of isolated subpopulations could attenuate the 
relationship between DNA adducts and carcinogen exposure. Although granulocytes seem to have a minor contribution 
to DNA adduct levels in peripheral blood, they play an important role in the formation of DNA adducts in BAL-cells; 
activated granulocytes release myeloperoxidase, which was found to increase DNA adduct levels in target cells by 
increased metabolic activation of pre-carcinogens and by the inhibition of DNA repair. Information on the influx of 
granulocytes into the lung and their subsequent activation is thus required to establish a more reliable dose-response 
relationship. The analysis of DNA adducts in separated cell-types present in BAL has not yet been performed. It should 
be recommended, if feasible in molecular epidemiological studies, to separate WBC-subpopulations and to characterize 
cells in BAL before the analysis of DNA adducts. 
 
O#23 
32P-postlabelling DNA adducts and lung cancer risk in Gen-Air, a case-control study nested in the EPIC 
investigation 
 
M. Peluso1, A. Munnia1, D.  Palli1, and P. Vineis2, in behalf of the Gen-Air participants 
1. CSPO-Scientific Institute of Tuscany Region, Florence, Italy; 2. Imperial College London, London, UK and 
University of Turin, Turin, Italy. 
 
Air pollution has been reported to increase lung cancer risk. The risk of lung cancer death has been suggested to 
increase by 8% for every 10 micrograms of fine particles in a cubic meter of inhaled air. In the present case-control 
study nested in the EPIC investigation, we investigated prospectively the ability of DNA adducts to predict cancer in 
non-smokers in 10 European countries (France, Denmark, Germany, Greece, Italy, The Netherlands, Norway, Spain, 
Sweden, United Kingdom). Cases included newly diagnosed lung cancer (N=115), upper respiratory cancers (pharynx, 
larynx) (N=82), bladder cancer (N=124), leukemia (N=166) and COPD or emphysema deaths (N=77), accrued after a 
median follow-up of 7 years among the EPIC former smokers and never smokers. Three controls per case were 
matched for questionnaire analyses, and two controls per case for laboratory analyses. Matching criteria were gender, 
age, smoking status, country of recruitment, and follow-up time. Individual exposure to air pollution was assessed 
using concentration data from monitoring stations in routine air quality monitoring networks. Leukocyte DNA adducts 
were blindly analysed using the 32P-postlabelling technique. DNA adducts were associated with the subsequent risk of 
lung cancer, with an odds ratio of 1.86 (95% CI 0.88-3.93) when comparing detectable versus non-detectable adducts. 
The association with lung cancer was stronger in never smokers (OR=4.04; 1.06-15.42) and among the younger age 
groups. After exclusion of the cancers occurring in the first 36 months of follow-up, the OR was 4.16 (1.24-13.88). A 
positive association was found between DNA adducts and O3 concentration, indicating that the average levels of O3 
play a role in the modulation of DNA adducts of non-smokers. Gen-Air study suggests that leukocyte DNA adducts 
may predict lung cancer risk of never smokers. Besides, the association of DNA adduct levels with O3 indicates a 
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O#24 
Sources of adducts releasing 4-hydroxy-1-(3-pyridyl)-1-butanone (HPB) from DNA and haemoglobin in humans 
 
E. Richter, W. Zwickenpflug, S. Tyroller, J. Wilp, D. Hölzle, D. Schlöbe, and M. Maier 
Walther Straub Institute of Pharmacology and Toxicology, Ludwig-Maximilians-University, Munich, Germany. 
 
Recently, the tobacco-specific nitrosamines (TSNA), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and N’-
nitrosonornicotine (NNN), have been classified by IARC as carcinogenic for humans. From determination of urinary 
NNK metabolites it can be concluded that smokers take up at least 100-fold higher amounts of TSNA than nonsmokers. 
However, HPB-releasing haemoglobin adducts resulting from metabolic activation of NNK and NNN did not show the 
expected specificity for smoking. Using an improved analytical method we found about sixfold higher levels of HPB-
releasing adducts in lung DNA from smoking (N=22; Mean±SE: 385±56 fmol HPB/mg DNA) compared to 
nonsmoking (N=12; 67±18 fmol/mg; p<0.0001) lung cancer patients undergoing lung surgery. In a subset of these 
patients haemoglobin adducts were only marginally higher in smokers (N=14; 60±13 fmol/g haemoglobin) compared to 
nonsmokers (N=8; 41±11 fmol/g; n.s.) and did not correlate with lung DNA adducts. In tumour-free sudden death 
victims current smoking status was verified by determination of cotinine in urine or blood. The differences in lung DNA 
adducts between 49 active smokers and 34 nonsmokers (91±19 versus 50±7 fmol/mg DNA; n.s.) were much lower in 
sudden death victims than in lung cancer patients. Even higher adduct levels were found in the mucosa close to the 
oesophageal-gastric junction. These mucosal adducts were completely independent of the smoking status and did not 
correlate with adducts in the lung. The tobacco alkaloid myosmine could be an important tobacco-independent source of 
HPB-releasing adducts for several reasons. Myosmine has been found in a large variety of edible plants. Independent 
from smoking status, myosmine is present in human plasma and saliva in the lower ng/ml range indicating daily uptake 
of mg amounts of myosmine from the diet. Finally, due to its imine structure myosmine is not only nitrosated rapidly to 
NNN but gives rise to reactive precursors of HPB by nitrosative as well as peroxidative mechanisms.  
 
O#25 
Dietary DNA adducts: heterocyclic amines and pesticides 
 
W. Pfau 
GAB-Consulting, Lamstedt, Germany. 
 
Diet is influencing human cancer risk and, among others, dietary residues of plant protection products (PPP) and 
heterocyclic aromatic amines (HCA) derived from frying or grilling meat have been suspected as contributing factors. 
PPP are a heterogeneous group comprising diverse chemical structures and various toxicological profiles. Experimental 
studies on the formation of DNA adducts by PPP are lacking confirmation and structural characterisation of adducts. 
Using the ³²P-postlabelling assay isolated studies have reported on elevated DNA modification levels in human 
peripheral lymphocytes upon occupational exposure towards PPP but DNA adducts were not characterised as PPP-
derived. No association of DNA modifications in humans with dietary intake of residual plant protection products have 
been reported, and, considering also the low residue levels, are not to be expected. The current re-evaluation of all 
existing PPP according to Directive 91/414/EC reduces health risks from dietary residues of PPP or occupational 
exposure to PPP in the EU. This process is, in fact, eliminating genotoxic active substances including those that have 
been shown experimentally to induce DNA adducts. There are about twenty different but structurally similar HCA. 
These have been demonstrated to be genotoxic, to form DNA adducts and to induce tumours in rodents. HCA-derived 
DNA adducts in human tissues have been identified only in a few studies using ³²P-postlabelling, immunochemical or 
mass spectrometric methods. Elevated levels of DNA modification in humans with a high intake of fried meat have 
been demonstrated in isolated studies. Several case control studies confirmed the association of high dietary intake of 
HCA and increased human cancer risk of the colon, breast and pancreas while no epidemiological association of dietary 
PPP-residues and cancer risk has been demonstrated. 
 
O#26 




Department of Toxicology, University of Würzburg, Germany. 
 
The biological significance of DNA adducts as a risk factor for mutation and cancer is under continuous debate. In view 
of the background rate of DNA damage this question could be addressed quantitatively by relating increments of DNA 
adducts from an exogenous source to the increments measured for other endpoints of genotoxicity. In this study, 
background levels of four adducts, O6-methyl-2'-deoxyguanosine (O6-mdGuo) and 7-methylguanine (7mG), 8-oxo-7,8-
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dihydro-2'-deoxyguanosine (8-oxodGuo) and 1,N6-etheno-2'-deoxyadenosine (εdAdo) were measured by LC-MS/MS in 
DNA isolated from large batches of L5178Y mouse lymphoma cells treated with methyl methanesulfonate (MMS) at 0, 
50, 100, 200 µM concentration. Aliquots of the cell suspension were used to perform simultaneously (i) the alkaline 
version of the comet assay, (ii) the micronucleus test, and (iii) the thymidine kinase tk+/- gene mutation assay. Means 
and standard deviations from at least four independent replicate studies were determined for the four adducts and the 
three biological endpoints, and increments above control were expressed in relative terms. Fifty µM MMS resulted in a 
1.6 to 2.2-fold increase above background for the biological endpoints, whereas both O6-mdGuo and 7mG increased 
about 8-fold. At 100 µM MMS, the biological endpoints showed 2.6 to 4.4-fold increases, while the factors for both O6-
mdGuo and 7mG were 19-fold. At 200 µM, the respective factors ranged from 4.4 to 7.5 for general genotoxicity and 
were 28 and 189, respectively, for the guanine methylations. No dose-related increase was observed for either 8-
oxodGuo or dAdo. Except for the sublinear dose response observed for 7mG at high dose, linearity could not be 
rejected for the other endpoints. Our data indicate that DNA-adduct formation as a first interaction of a genotoxic agent 
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32P-Postlabelling analysis of thymine dimer in urine from children of different skin types 
 
T. Sandberg1, N. Kotova2, P.C. Turner3, A. Sylla4, M.S. Diallo4, C.P. Wild3, and D. Segerbäck1 
1. Department of Biosciences and Nutrition, Karolinska Institute, Stockholm, Sweden; 2. Department of Genetics, 
Microbiology, and Toxicology, Stockholm University, Stockholm, Sweden; 3. Molecular Epidemiology Unit, 
University of Leeds, Leeds, UK; 4. Institut Pasteur de Guinée, Kindia, Republic of Guinea. 
 
Formation of UV induced DNA lesions is associated with the development of different forms of skin cancer. The 
predominant lesion induced is a thymine-thymine (T=T) which following DNA repair can be released intact into the 
urine. A highly sensitive 32P-postlabelling assay has been developed, and it was shown that the amount of excreted T=T 
in urine was directly correlated to the UV dose received. Epidemiological studies show that dark skin is highly 
protective against skin cancer. In this study we compared urinary T=T levels in children of different skin types after 
exposure to natural sunlight. Urine samples were collected from Swedish children of Caucasian origin and in black 
children from Guinea, West Africa. The T=T levels in the Guinean children did not differ dramatically from that of 
Swedish children in spite of the higher UV exposure in Africa. A preliminary assessment of the difference after 
correction for the different UV doses received by the two populations indicate that the amount of lesions in the African 
children were 1-2 orders of magnitude less than in the Swedish children. This protection factor of black skin is in line 
with what has been found when analysing DNA damage in skin earlier, and shows that other factors than just DNA 
damage are important to determine the risk of skin cancer. 
 
P#2 
Ochratoxin A (OTA)-DNA adduct detection as a useful biomarker of OTA exposure and for studies on 
molecular mechanism of OTA carcinogenicity 
 
A. Pfohl-Leszkowicz1, V. Faucet-Marquis1, M. Tozlovanu1, F. Pont2, P. Mantle3, M. Castegnaro4, and R. 
Manderville5 
1. Laboratoire de Génie Chimique, UMR CNRS/INPT/UPS n° 5503, Department BioSyM, INP/ENSAT 1, Avenue 
Agrobiopôle, BP 32607, 31326 Auzeville-Tolosane, France; 2. Department of Mass Spectrometry IFR 30, Unit 
INSERM U563, CHU Purpan, 31024 Toulouse, France; 3. Imperial College London, Department of Environmental 
Science & Technology, SW7 2AZ London, UK; 4. Consultant, Les Collanges, 07 420 Saint-Jean Chambre, France; 
5. Department of Chemistry, University of Guelph, Guelph, N1G 2W1 Ontario, Canada. 
 
Ochratoxin A (OTA) is a nephrotoxic and carcinogenic mycotoxin, suspected of being the etiological agent of Balkan 
endemic nephropathy (BEN) and associated urinary tract cancers.  Conflicting results have been obtained regarding the 
genotoxicity of OTA and its ability to react directly with DNA upon oxidative bioactivation to yield covalent DNA 
adducts. This presentation gives an overview of data studying the metabolic pathways involved in OTA genotoxicity 
and the nature of DNA adduction observed in cells or tissues. By 32P-Post-labelling technique, a dose- and time-
dependent DNA adduct formation is observed in vivo (mice, rat, pig) and in vitro (human or opposum cells cultures; 
microsomes incubations). Use of several inducers or inhibitors of biotransforming enzymes (including cytochrome 
P450, cyclooxygenase, lipoxygenase, glutathione-S-transferase), demonstrated that OTA is biotransformed into 
genotoxic derivatives damaging for DNA. Authentic C8dG-OTA standards have been synthesised by photo-oxidation. 
Both of them (C-C8 & O-C8) comigrate on TLC with two adducts formed by in vitro incubation of OTA in the 
presence of kidney microsomes, and in vivo in kidney of pig or rodent fed OTA as well as in kidney and bladder tumour 
of humans naturally exposed to OTA. DNA-binding of OTA is related to formation of OTA-quinone derivatives, some 
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Evaluation of ELISA and HPLC-MS/MS methodology for the analysis of 8-oxo-7,8-dihydro-2’-deoxyguanosine 
in saliva and urine 
 
M.D. Evans1, R. Singh3, G.K. Hall1, V. Mistry1, T. Duarte1, P.B. Farmer3, and M.S. Cooke1,2 
1. Radiation & Oxidative Stress Group, Department of Cancer Studies and Molecular Medicine & 2. Department of 
Genetics, University of Leicester, RKCSB, Leicester Royal Infirmary, UHL NHS Trust, Leicester, LE2 7LX, United 
Kingdom; 3. Cancer Biomarkers and Prevention Group, Biocentre, University of Leicester, University Road, 
Leicester, LE1 9HN, United Kingdom. 
 
Background: 8-oxo-7,8-dihydro-2’deoxyguanosine (8-oxodG) has often been measured in urine as a marker of DNA 
oxidation, by immunochemical or chromatographic methods. Whilst ELISA is a frequently used means of assessing 8-
oxodG in biological fluids, differences in baseline urinary 8-oxodG levels, compared to chromatographic techniques, 
has raised questions regarding the specificity of immunoassays. Recently, ELISA of salivary 8-oxodG has been used to 
report on periodontal disease. 
Methods: Urine and saliva samples were collected from 30 healthy subjects (12 males, 18 females, age range 20-48) for 
analysis. Comparison of salivary and urinary 8-oxodG levels, using two commercially available ELISA kits, to high 
performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS), with prior solid phase extraction 
(SPE), was performed.  The SPE/HPLC-MS/MS methodology was developed based on methodology reported by Lin et 
al. (H.S. Lin et al. (2004) Biochem. J. 380:541-548). Synthesis, purification and characterisation of [15N5]-8oxodG for 
HPLC-MS/MS was done in house. Urinary creatinine values were also determined by The Department of Clinical 
Biochemistry at Leicester Royal Infirmary. 
Results: Salivary 8-oxodG values were obtained with both ELISA kits, although HPLC-MS/MS results for 8-oxodG in 
saliva approached the limit of detection for this assay. As the limit of detection for the HPLC-MS/MS procedure is 
much lower than ELISA, we concluded that the assessment of salivary 8-oxodG by ELISA is not accurate. In contrast to 
previous studies, ELISA levels of urinary 8-oxodG (1.67 ± 0.53 pmol/µmol creatinine) were within the range reported 
previously only for chromatographic assays, although still significantly different to HPLC-MS/MS (0.41 ± 0.39 
pmol/µmol creatinine; p = 0.002). Furthermore, no correlation with HPLC-MS/MS was seen. 
Conclusions: These results question the ability of ELISA approaches to specifically determine absolute levels of 8-
oxodG in saliva and urine. On-going investigation in our laboratories aims to identify the basis of the discrepancy 
between ELISA and HPLC-MS/MS. 
 
P#4 
Urinary biomarkers of aflatoxin exposure in young children in Egypt and Guinea 
 
N. Polychronaki1,2, C. Wild3, H. Mykkänen1, M. Abdel-Wahhab4, A. Sylla5, M. Diallo5, H. El-Nezami1,2, and P. 
Turner3 
1. Department of Public Health and Clinical Nutrition, University of Kuopio, Kuopio, Finland; 2. Food and Health 
Research Centre (ETTK), University of Kuopio, Kuopio, Finland; 3. Molecular Epidemiology Unit, Leeds Institute 
for Genetics, Health and Therapeutics, University of Leeds, Leeds, UK; 4. Department of Food Toxicology and 
Contaminants, National Research Centre, Dokki, Egypt; 5. Institut Pasteur de Guinée (IPG), Kindia, Republic of 
Guinea. 
 
Chronic exposure to the fungal toxins aflatoxins (AFs) is considered to be a major risk factor in the development of 
primary liver cancer. In parts of Africa AF exposure is common and early life exposure could be a contributing factor 
towards the early onset of liver cancer in adulthood. This project assessed the level of exposure of children to aflatoxin in 
Egypt (predicted moderate aflatoxin exposure) and Guinea (predicted high aflatoxin exposure) by measurement of AF 
metabolites in urine. Aflatoxins were extracted from urine samples of 50 Egyptian (aged 1-1.5 years old) and 50 Guinean 
children (aged 2-4 years old) by C18 cartridges and aflatoxin immunoaffinity columns and analyzed by HPLC-fluorescence. 
AFB1, AFB2, AFG1, AFG2 and AFM1 were detected in children’s urine and the identities of the aflatoxins were confirmed 
by spiking with aflatoxin standards and co-chromatography using different HPLC conditions. AF were less frequently 
present in Egyptian than Guinean children (38% Vs 86%) with statistically significant differences in prevalence for most of 
the detected toxins (AFB1 (2% Vs 16%, p= 0.016), AFB2 (10% Vs 58%, p= 0.000), AFG1 (4% Vs 2%), AFG2 (24% Vs 
36%, p= 0.190) and AFM1 (8% Vs 64%, p= 0.000). For AFM1 the mean levels in Guinea were 18-fold higher than in Egypt. 
Worldwide there is a scarcity of urinary biomarker data for AF exposure in children. Overall AF exposure in Egypt is 
modest in comparison to Guinea though it should be noted that more of the Egyptian children in this study were still at least 
partially breast feeding, and thus may be protected against exposure due to the limited passage of AF into breast milk. These 
data would suggest that measures to reduce AF exposure in both regions are important although the situation is particularly 
pressing in Guinea where exposure is more prevalent and at higher levels. 
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P#5 
Assessment of the relative contribution of exogenous and endogenously derived N7-(2-hydroxyethyl)guanine 
adducts in ethylene oxide treated rats 
 
D.A. Marsden, D.J.L. Jones, J.H. Lamb, R.J.R. Crookston, P.B. Farmer, and K. Brown 
Cancer Biomarkers and Prevention Group, Biocentre, University of Leicester, Leicester LE1 7RH, United Kingdom. 
 
Ethylene oxide (EO) is a widely used intermediate in the chemical industry and is also formed endogenously from the 
metabolism of ethylene, which is generated during normal physiological processes. EO reacts with DNA, primarily 
forming N7-(2-hydroxyethyl)guanine adducts (N7-HEG), which can be used as a biomarker of exposure and potential 
cancer risk.  In order to accurately determine the increase in DNA damage caused by low exposures to EO we have 
established background and induced levels of N7-HEG adducts in 6-week old male F-344 rats (3/group) using a liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) assay. Endogenous N7-HEG was present in all tissues 
examined, ranging from 1.1-3.5 adducts/108 nucleotides. Following administration (i.p.) of a single or three daily doses 
of EO (0.01-1.0 mg/kg) N7-HEG adducts increased in a dose dependent manner, with the highest levels achieved in the 
liver.  In the 3-day study, hepatic adduct levels were elevated 2h after the final dose, subsequently decreasing over time, 
with a second increase observed at 10h.  Since a similar trend was observed in other tissues in both treated and control 
animals, this suggests a natural variation throughout the day in the production of endogenous adducts is responsible for 
the later increase.  To examine the effects of lower EO concentrations, including doses that should attain blood levels 
several orders of magnitude lower than that produced after occupationally relevant exposures, 14C-labeled EO was 
administered to rats (4/group) at (0.1-0.0001 mg/kg), for three consecutive days. This resulted in a dose dependent 
increase in tissue concentrations of 14C-EO (~2-5000 fmols EO/mg liver). DNA samples extracted from tissues are 
currently being analysed for the presence of background and exogenous N7-HEG adducts by LC-MS/MS and 
accelerator mass spectrometry respectively, which will also allow determination of whether exogenous EO exposure 
modulates background levels of N7-HEG adducts. Funded by the American Chemistry Council (MTH0311-02). 
 
P#6 
DNA modification by 1-nitroacridine derivatives. Interstrand crosslinking in nuclear and mitochondrial DNA of 
tumor cells by 1-nitroacridine C-1748 and Nitracrine 
 
A. Dyrcz and J. Konopa 
Department of Pharmaceutical Technology and Biochemistry, Gdańsk University of Technology, Gdańsk, Poland. 
 
The significant role for biological activity of several antitumor compounds is their ability to induce DNA adducts and 
DNA crosslinking. Earlier studies proved that mitochondrial DNA (mtDNA) was much more susceptible to covalent 
modification than nuclear DNA (nDNA) by different xenobiotics, particularly DNA alkylating agents. The induction of  
interstrand mtDNA crosslinking was demonstrated only for few antitumor drugs. Our aim was to investigate the ability 
of 4-methyl-1-nitroacridine derivative C-1748, developed in our department, selected to phase I clinical trial, to form 
crosslinks in mtDNA of tumor cells and compare it with similar ability to bind nDNA. Compared to its parent analogue 
Ledakrin (Nitracrine), C-1748 is definitely less toxic to patients. Both compounds  crosslink DNA after metabolic 
activation.All experiments were carried out on tumor cells of human colon cancer HCT-8. The mtDNA crosslinking 
were investigated with the electrophoretic Hartley’s method and detected with the aid of specific molecular mtDNA 
probe in Southern hybridization. Whereas nDNA crosslinking were conducted with the usage of modified, radioactive 
Parsons method. Both 1-nitroacridines were able to induce mtDNA and nDNA crosslinks in a dose-dependent manner 
after 6 and 14 hours of cells’ treatment. There was no significant difference between first crosslinking bonds which 
appeared in mtDNA and nDNA. We detected them for 0,5 µM of C-1748 concentration and 0,05 µM of Nitracrine. The 
level of crosslinking modification was much higher for mtDNA and gained 100 % for 5 µM of C-1748. We did not 
detect this for Nitracrine as it induced mtDNA fragmentation above 1 µM concentration. We observed also that 
Nitracrine was stronger and faster crosslinking agent than C-1748 derivative. To conclude, mtDNA can be the 
molecular target for both 1-nitroacridines. 
 
P#7 
Genotoxic effect of PAHs and their mixtures in THP-1 cells 
 
Z. Novakova, B. Binkova, O. Sevastyanova, R.J. Sram, and J. Topinka 
Laboratory of Genetic Ecotoxicology, Institute of Experimental Medicine, Academy of Sciences of the Czech 
Republic, Videňska 1083, 142 20 Prague 4, Czech Republic. 
 
To find an appropriate in vitro model for studies on genotoxic potential of polycyclic aromatic hydrocarbons (PAHs) 
and their real environmental mixtures, human acute monocytic leukaemia cells THP-1 were incubated with individual 
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PAHs, their synthetic mixtures and the organic extract from particulate matter of the ambient air. We determined bulky 
DNA adducts by 32P-postlabelling and the expression of p53 and p21WAF1 proteins by Western blotting. Out of 4 
carcinogenic PAHs tested (benzo[a]pyrene, B[a]P; dibenzo[a,l]pyrene, DB[a,l]P; benz[a]anthracene, B[a]A; 
benzo[b]fluoranthene, B[b]F) the highest DNA adduct forming activity was observed for DB[a,l]P inducing more than 
70 adducts/108 nucleotides at very low concentration of 10 nmol/l. The incubation of THP-1 cells with a synthetic 
mixture of 8 carcinogenic PAHs (c-PAHs) prepared proportionally to the content of individual c-PAHs in real 
environmental mixtures (B[a]P in concentrations of 0.1, 0.5 and 1 µmol/l was taken as a basis) resulted in significantly 
lower DNA adduct levels as compared with DNA adduct levels resulting from single components. For example, at 
B[a]P concentration of 0.1 µmol/l, 26-fold higher DNA adduct levels were observed than for c-PAH mixture containing 
equal B[a]P concentration. Even lower DNA adduct levels were induced by extractable organic matter (EOM) from 
ambient air indicating inhibition effect of various extract components. The results suggest a competition for the 
metabolic activation enzymes, their saturation and/or inactivation by PAH metabolites. Compared to other cell cultures 
used in genetic toxicology, THP-1 cells exhibited much lower DNA adduct levels induced by PAHs. We did not 
observed induced levels of both p53 and p21WAF1 proteins by any PAHs and mixtures. This finding is in agreement with 
our previous studies suggesting that certain minimum of DNA adduct levels should be reached to observe induction of 
these proteins. We concluded that due to their limited metabolic capacity THP-1 cells are not sensitive enough and 
therefore they are not suitable model system for in vitro testing of genotoxicity of PAHs and complex mixtures of 
organic air pollutants. The work was supported by Czech ministry of Environment, grant No. VaV/740/05/03. 
 
P#8 
DNA modification by 1-nitroacridine derivatives. Comparison of 32P-Postlabeling and restriction enzyme 
analysis method for the detection of DNA adducts formed by 1-nitroacridines C-1748 and C-857 
 
J. Lewandowska, A. Bartoszek, and J. Konopa 
Gdansk University of Technology, Dept. of Pharmaceutical Pharmacology and Biochemistry, Gdansk, Poland. 
 
4-Substituted 1-nitroacridines represent a new group of acridine derivatives synthesized at Gdansk University of 
Technology. Compared to parent 1-nitroacridines, these compounds exhibit lower toxicity and enhanced antitumor 
efficacy. The leading derivative 4-methyl-1-nitroacridine denoted C-1748 is being prepared for the I phase clinical 
evaluation towards prostate cancer. In the present study, we compare DNA binding properties of C-1748 and the parent 
4-unsubstituted analogue C-857. Two methods were used in this study. 32P-Postlabelling technique was employed for 
the detection of DNA adduct formation in cellular and cell-free systems. The DNA adducts were studied in HT29 
(colon cancer) and LNCaP (prostate cancer) cells as well as in cell-free system employing DTT or microsomes for the 
activation of the compounds. C-1748 and C-857 gave rise to different patterns of 4-6 adducts spots. However, for a 
given compound the same DNA patterns were observed in all studied systems. Also, in cell-free system, the same DNA 
adduct patterns were found with using the different systems activation (DTT or microsomes). DNA modification level 
was 1 adduct per 104 nucleotides in the cells, and 1 adduct per 105 nucleotides in cell-free system. The second 
technique, developed by us, is a method which exploits restriction enzymes to the detection of covalent modification of 
specifically designed PCR-amplified DNA fragment. This amplicon includes two restriction sites recognized by 
enzymes: MspI (GC specific) and Tru1I (AT specific). The inhibition of cleavage was a measure of covalent 
modification of the restriction site(s) simultaneously pointing at the kind of base pairs involved in DNA binding. By this 
approach we were able to follow the kinetics of covalent DNA modification by C-1748 and C-857 and to determine 
their base pair specificity. 
 
P#9 
Seasonal variability in genotoxic potential of urban air particulate matter 
 
O. Sevastyanova, Z. Novakova, K. Hanzalova, B. Binkova, R.J. Sram, and J. Topinka 
Institute of Experimental Medicine AS CR, Prague, Czech Republic. 
 
The main aim of this study was to compare genotoxic potential of organic extracts from urban air particles collected in 
various seasons in the center of Prague (Czech Republic). For this purpose we analyzed DNA adduct forming activity of 
organic extracts from urban air particles (PM10) in human hepatoma cell line HepG2. DNA adducts were analyzed by 
32P-postlabelling with nuclease P1 enrichment. Concentrations of PM10 were 36.9 µg/m3, 39.0 µg/m3, 62.6 µg/m3 in 
summer, autumn and winter, respectively. Corresponding EOM contents were 5.0 µg/m3 (13.9% of PM10), 6.7 µg/m3 
(17.2%) and 14.9 µg/m3 (23.8%). The total DNA adduct levels induced by 10 µg EOM/ml were 17.7; 37.2 and 19.5 
adducts/108 nucleotides in summer, autumn and winter, respectively. However, when the EOM quantities per m3 were 
taken into the consideration summer sample exhibited 3-fold lower genotoxicity than those of autumn and winter, while 
difference between autumn and winter samples was not significant: 88.6, 249 and 291 adducts (in relative units), 
respectively. Higher concentrations of EOMs induce toxic effects. Although concentration PM10 and EOM content in 
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autumn were significantly lower than in winter, genotoxic potential of ambient air in autumn and winter was almost 
equal. There are significant positive correlations between B[a]P and c-PAH contents in EOM from various sampling 
periods and total DNA adduct levels detected in the EOM treated samples. These findings support hypothesis that B[a]P 
and c-PAH contents in EOMs are the most important factors for their genotoxic potential. Thus, estimation of the 
genotoxic potential of ambient air and prediction of health risk should be based mainly on concentration of c-PAHs and 
biological activity of extracts, while amount of particles and EOM content are not crucial determinants. Supported by 




Improvement of 32P-Post-labelling method for the detection of Ochratoxin A-DNA adducts 
 
V. Faucet-Marquis1,  P. Mantle2,  M. Castegnaro3, R. Manderville4,  and A. Pfohl-Leszkowicz1 
1. Laboratoire de Génie Chimique, UMR CNRS/INPT/UPS n° 5503, Department BioSyM, INP/ENSAT 1, Avenue 
Agrobiopôle, BP 32607, 31326 Auzeville-Tolosane, France; 2. Imperial College London, Department of 
Environmental Science & Technology, SW7 2AZ London, UK, 3. Consultant, Les Collanges, 07 420 Saint-Jean 
Chambre, France; 4. Department of Chemistry, University of Guelph, Guelph, N1G 2W1 Ontario, Canada. 
 
A recent EU-funded research programme on mechanisms of renal carcinogenicity of ochratoxin A (OTA) has addressed 
the genotoxicity debate because of dispute over the DNA adducts that have been demonstrated by 32P-post-labelling 
methodology for the toxin in French laboratories in the past 20 years, and the failure to reproduce such evidence 
elsewhere. DNA adducts of some genotoxic chemical carcinogens are readily demonstrated in many laboratories, but 
demonstration of the low maximum incidence associated with exposure to ochratoxin A (~100/109 nucleotides) is 
dependent on adherence to strict protocols for all the stages of DNA extraction, purification and the complex steps and 
specific reagents in 32P-Post-labelling.  Demonstration of adducts in renal DNA from rats exposed to very small 
amounts of ochratoxin A, more representative of natural exposure than of the doses necessary for maximum expression, 
require an even greater attention to analytical detail. DNA from rats treated by OTA, synthetic dG-OTA adduct and 
DNA from rat treated by aristolochic acid have been analysed by 32P-post-labelling technique (contact transfer or 
multidimensional) using different DNA extraction and chromatographic conditions. This allows us to demonstrate that 
the lack of OTA-DNA adduct detection by some teams is due to methodological problems, including incomplete 
hydrolysis and inappropriate solvent of migration.  
 
P#11 
DNA adduct formation by genotoxicants from Brassicaceae 
 
C. Baasanjav and H.R. Glatt 
German Institute of Human Nutrition, Potsdam-Rehbrücke, Department of Nutritional Toxicology, 14558 Nuthetal, 
Germany. 
 
Plants have to defend themselves against infecting microorganisms and herbivores animals. We hypothesized that 
reactive chemicals released after damage of the plant would be effective against all kinds of enemies; some of these 
reactive molecules might also damage DNA. To test this hypothesis, we developed a simple test system: we 
homogenised plants, incubated the homogenate for varying times and then analysed the endogenous DNA – as a 
surrogate target – for the presence of adducts using the 32P-postlabelling assay. Under these conditions, a time-
dependent formation of adducts was detected with various plants. Here, we present data from Brassicaceae plants. Four 
major and some minor adduct spots were distinguished in Arabidopsis. We found a similar DNA adduct pattern in other 
Brassicaceae plants such as broccoli, cauliflower and rape, suggesting the occurrence of the same or similar genotoxic 
compounds in many members of this plant family. Subsequently, we treated mammalian cells in culture as well as 
bacteria (Ames’s Salmonella strains) with plant homogenate. This led to the formation of the same patterns of adducts 
as detected in the endogenous DNA. Moreover, gene mutations were induced in these model systems. Finally, we 
conducted studies in human volunteers chewing broccoli. Whereas no adducts were detected in buccal mucosa cells 
taken before chewing raw broccoli, very high levels of Brassicaceae-typical adducts (up to 1800 per 108 nucleotides) 
were detected afterwards (at least for 9 h, the latest time point analyzed). Negligible levels of adducts were found when 
steamed rather than raw broccoli was consumed. We are conducting feeding experiments in laboratory animals with raw 
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P#12 
Markers of inflammation and aberrant CpG-island methylation as biomarkers of vulnerability to colorectal 
cancer 
 
H.L. Greetham1, A. Coupe1, I.T. Johnson2, and J.C. Mathers1 
1. Human Nutrition Research Centre, School of Clinical Medical Sciences, Newcastle University, Newcastle upon 
Tyne, NE1 7RU, UK; 2. Gastrointestinal Biology and Health, Institute of Food Research, Norwich Research Park, 
Norwich, Norfolk, NR4 7UA, UK. 
 
The adenoma-carcinoma sequence leads to formation of localised precancerous lesions (adenomatous polyps).  These 
events are associated with abnormalities of gene expression caused by specific mutations and epigenetic changes, 
notably aberrant CpG-island methylation. In our studies we are seeking to identify molecular abnormalities in the 
colorectal mucosa that can be used as biomarkers of susceptibility to neoplasia. The potential of sub-clinical levels of 
colorectal inflammation playing an important role in sporadic colorectal cancer has recently been examined (Erlinger et 
al., 2004).  Furthermore, it appears that there may be a direct association between markers of systemic and colonic 
inflammation (Poullis et al., 2003). In the current study we have recruited 100 patients proven at endoscopy to be free of 
colorectal neoplasia and are recruiting a second group of 100 patients with a history of adenomatous polyps. We are 
recording anthropometric data (height, body-weight and waist and hip circumferences), physical activity via a lifestyle 
questionnaire, and nutritional data via a food frequency questionnaire and blood and urine analyses. C-reactive protein 
is being measured as a systemic marker of inflammation in serum (using hs-CRP) and faecal calprotectin and IL-6 as 
markers of colorectal inflammation. This should allow us to determine whether systemic inflammation (associated with 
high body-weight and adiposity) is linked with low-grade colorectal mucosal inflammation, and if this condition is 
associated with higher vulnerability to colorectal neoplasia. If proven, plasma and faecal markers of inflammation may 
be useable as surrogate biomarkers of early neoplasia.  The methylation status of the promoter regions of a panel of 
genes will be quantified (Belshaw et al., 2004), and the relationship between inflammation and gene methylation 
investigated. This study will help define the links between colorectal inflammation and gene silencing through CpG-
island methylation and determine whether the effects are related to diet, lifestyle and body fatness. This project is 
funded by the Food Standards Agency (Project No. N12016). 
 
References: 
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human stools to detect aberrant CpG-island methylation of genes implicated in colorectal cancer. Cancer Epidemiol 
Biomarkers Prev., 13, 1495-1501. 
Erlinger TP, Platz EA, Rifai N, and Helzlsouer KJ (2004) C-reactive protein and the risk of incident colorectal cancer.  
JAMA., 291, 585-590. 
Poullis A, Foster R, Shetty A, Fagerhol MK, and Mendall MA (2004) Bowel inflammation as measured by fecal 




Development of an LC-MS/MS method to measure DNA adducts formed by platinum based chemotherapeutic 
agents: role of intrastrand crosslinks in resistance 
 
R.C. Le Pla1, K. Ritchie2, C. Henderson2, C.R. Wolf2, G.M. Almeida3, G.D.D. Jones3, C.F. Harrington1, and P.B. 
Farmer1 
1. Cancer Biomarkers and Prevention Group, University of Leicester, Leicester LE1 7RH, UK; 2. Imperial Cancer 
Research Fund Molecular Pharmacology Unit, Biomedical Research Centre, Ninewells Hospital and Medical 
School, Dundee, DD19SY, UK; 3. Cancer Studies and Molecular Medicine, University of Leicester, Leicester, LE1 
7RH, UK. 
 
Cellular resistance, both intrinsic and acquired, poses a problem in the effectiveness of platinum based chemotherapy. 
The cytotoxic activity of platinum based chemotherapeutic agents is derived from their ability to react with cellular 
DNA. Cisplatin and oxaliplatin bind to the N7 position of the purine DNA bases forming mainly intrastrand crosslinks 
between adjacent guanines (GG) (~ 65%) and between an adjacent adenine and guanine (AG) (~25%) and a small 
percentage of monofunctional adducts, DNA-protein adducts and interstrand crosslinks. Several mechanisms have been 
proposed to account for the resistance of some tumours to platinum based therapies including increased DNA repair, 
increased lesion tolerance, defective apoptosis response, increased deactivation by intracellular thiol containing 
molecules and decreased intracellular accumulation of the drug. We report the development of an LC-MS/MS method 
for measuring GG and AG intrastrand crosslinks formed by cisplatin and oxaliplatin and compare the formation and 
persistence of intrastrand crosslinks between cell lines known to have high and low resistance to these drugs. Wild type 
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and glutathione S transferase P1 null mice (GSTP1 null) were treated with oxaliplatin (10 mg/kg). No significant 
difference was observed in the level of intrastrand crosslinks formed by oxaliplatin between the mice strains in liver, 
kidney and lung DNA. Adduct levels were greatest in liver and lowest in lung tissue. 
 
P#14 
DNA adduct formation by diet induced endogenously formed nitroso compounds 
 
G.G.C. Kuhnle and S.A. Bingham 
Diet & Cancer Group, MRC Dunn Human Nutrition Unit, Wellcome Trust/MRC Building, Hills Road, Cambridge, 
CB2 2XY, UK. 
 
Red and processed - but not white meat and fish - are associated with colorectal cancer. The consumption of red and 
processed meat causes a dose-dependent increase in endogenously formed faecal nitroso compounds (ATNC) and these 
compounds may be the chemical link between red meat and cancer. Nitroso compounds (NOCs) are known carcinogens 
and can cause the formation of DNA adducts. Recently, we showed a link between meat consumption, faecal ATNC 
and the NOC-specific DNA adduct 6O-carboxymethyl-2’-deoxy-guanosine (6O-CMG) (LEWIN et al., 2006). To 
elucidate this link further, it is important to identify these compounds, to investigate their formation and mode of action 
in vivo. In a controlled study, twelve healthy volunteers were fed three different diets containing different amounts of 
red meat and fibre (vegetarian, high red meat and high fibre, high red meat). Faecal samples were collected and 
analysed for total nitroso compounds, nitrosyl iron, nitroso thiols and haem content. Approximately 60% of the total 
amount of nitroso compounds formed following a meat diet consisted of nitrosyl iron compounds, approximately 30% 
of nitrosothiols; by difference, N-nitroso compounds only contribute 10%. ESR spectra showed that nitrosylated haem, 
e.g. nitroso-haemoglobin or nitroso-myoglobin, are found in faecal homogenates following a high meat diet. 




Lewin MH, Bailey N, Bandaletova T, Bowman R, Cross AJ, Pollock J, Shuker DE, Bingham SA (2006) Red meat 
enhances the colonic formation of the DNA adduct O6-carboxymethyl guanine: implications for colorectal cancer 
risk. Cancer Res., 66, 1859-1865 
 
P#15 
Influence of metabolic modifiers on the DNA adduct formation of 1-hydroxymethylpyrene and 1-hydroxy-
methyl-8-methylpyrene in the rat  
 
C. Donath1, M. Stephani1, A. Seidel2, and H.R. Glatt1 
1. German Institute of Human Nutrition Potsdam-Rehbrücke, Department of Nutritional Toxicology, Nuthetal, 
Germany; 2. Biochemical Institute for Environmental Carcinogens, Grosshansdorf, Germany. 
 
Some alkylated polycyclic aromatic hydrocarbons (alk-PAH), such as methylpyrenes, are much more abundant in the 
environment than the reference PAH benzo[a]pyrene. Two of these compounds, 1-methylpyrene and 1,8-dimethyl-
pyrene, are converted via benzylic hydroxylation and subsequent sulfonation to the corresponding reactive sulfuric acid 
esters, 1-sulfooxymethylpyrene and 1-sulfooxymethyl-8-methylpyrene, which are mutagenic and form DNA adducts in 
vitro and in vivo. Sulfonation of the benzylic alcohols 1-hydroxymethylpyrene (1-HMP) and 1-hydroxymethyl-8-
methylpyrene (1-HM-8-MP) as the critical activation step carried out by sulfotransferases competes with other reactions 
like oxidation by alcohol and aldehyde dehydrogenases that convert benzylic alcohols to stable, excretable carboxylic 
acids thus mediating an important detoxification reaction. To study the influence of several metabolic modifiers (penta-
chlorophenol, quercetin, 4-methylpyrazole, ethanol and disulfiram) on sulfotransferase-mediated bioactivation of 1-
HMP and 1-HM-8-MP male Wistar rats received a concurrent treatment with the benzylic alcohol and one of the 
metabolic modifiers, whereas control animals received the benzylic alcohol and the solvent only. DNA isolated from 
liver and kidney was then analysed for DNA adducts by 32P-postlabelling and DNA adduct levels of treatment and 
control groups were compared. Initial results demonstrate clear effects of the applied modifiers on DNA adduct levels 
caused by 1-HMP and 1-HM-8-MP due to alterations of the sulfotransferase-mediated bioactivation to reactive DNA 
binding species. A concurrent treatment of rats with benzylic alcohols and pentachlorophenol or quercetin, respectively, 
led to a decrease in DNA adduct levels compared to rats that only received the benzylic alcohol due to inhibition of 
sulfotransferase activity. In contrast, a concurrent treatment of rats with benzylic alcohols and 4-methylpyrazole, 
ethanol or disulfiram, led to increased DNA adduct levels due to inhibition of the oxidative detoxification pathway. 
Thus we conclude that the toxicological effects of some alkylated polycyclic aromatic hydrocarbons may be strongly 
affected by interaction with other chemicals that might be components of human nutrition (ethanol, quercetin) or used 
as drugs (4-methylpyrazole). 
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Reduction of oxidative DNA damage by a anthocyanin/polyphenolic rich fruit juice in an intervention study with 
patients on hemodialysis 
 
T. Spormann1, F.W. Albert2, T. Rath2, H. Dietrich3, F. Will3, G. Eisenbrand1, and C. Janzowski1 
1. Technical University Kaiserslautern, Division of Food Chemistry & Environmental Toxicology, Kaiserslautern, 
Germany; 2. Westpfalz-Klinikum, Kaiserslautern, Germany; 3. Research Institute Geisenheim, Department of Wine 
Chemistry and Beverage Technology, Geisenheim, Germany. 
 
Background: Patients with chronic renal failure undergoing hemodialysis (HD) are considered to face an elevated risk 
for cancer, artheriosclerosis and other diseases. This has been attributed in part to increased oxidative stress, resulting 
from bioincompatibility of the extracorporal blood circuit, malnutrition and other factors. Uptake of fruit juice with 
especially high flavonoid/polyphenol content has been shown to reduce oxidative cell damage in healthy probands 
(Weisel et al. Biotechnol. J., 1, 388, 2006) and might also be utilized as preventive measure in HD-patients. 
Methods: An intervention study is performed with mixed fruit juice (total phenols: 3478 mg/L). After a three week run-
in phase, 20 HD-patients (non-smokers, stable HD) consume for 4 weeks 200ml/d of the juice, followed by a three 
week wash-out phase. Blood sampling is performed weekly. DNA damage (COMET assay with/without 
formamidopyrimidine-DNA-glycosylase) and glutathione (kinetic photometric assay) in whole blood are monitored. 
Additionally, lipid peroxidation (HPLC/fluorescence of malondialdehyde) and the trolox equivalent antioxidant 
capacity (TEAC) are determined in plasma; DNA binding capacity of the transcription factor NfκB (ELISA) is 
monitored in primary blood mononuclear cells. 
Results: First results (obtained from 13 patients) show a strong decrease of total DNA damage (with FPG) during juice 
uptake (mean TI%: run-in: 5.3/juice uptake: 3, p<0.0005; juice uptake: 3/wash-out:, p<0.0005), basic DNA damage 
(without FPG) was also reduced (mean TI%: run-in: 0.61/juice uptake:0.51, p<0.05; juice uptake: 0.51/wash-out: 0.44, 
p=0.052). Correspondingly, an increase of total glutathione and of glutathione status was observed during the 
intervention, whereas modulation of the other markers was not apparent at present.   
Conclusions: The red fruit juice clearly shows a marked potential to reduce (oxidative) DNA damage in HD-patients. 




CYP1A1 up-regulation in MCF-7 cells following benzo[a]pyrene treatment occurs primarily during S-phase: a 
significant modulator of consequent genotoxicity 
 
F.L. Martin1, S.L. Allinson1, M.J. Walsh1, R. Hewitt1, K.J. Cole2, D.H. Phillips2, and H. Jiao1 
1. Biomedical Sciences Unit, Department of Biological Sciences, Lancaster University, Lancaster LA1 4YQ, UK; 2. 
Institute of Cancer Research, Brookes Lawley Building, Cotswold Road, Sutton SM2 5NG, UK. 
 
Pro-carcinogens, e.g., benzo[a]pyrene (B[a]P), may act as exogenous ligands of the aromatic hydrocarbon receptor and 
through this interaction modulate the susceptibility of target cell populations via the receptor-mediated up-regulation of 
cytochrome P450 (CYP) mixed function oxidases.  Using an approach to concentrate oestrogen-receptor positive breast 
carcinoma MCF-7 cells in different phases of the cell cycle whilst in culture, we examined whether this might serve to 
determine the level of B[a]P-induced up-regulation of CYP1A1, CYP1A2 or CYP1B1, and if this could then influence 
subsequent levels of DNA damage measurable either as single-strand breaks (SSBs) or B[a]P-DNA adducts.  Cell 
cultures were manipulated to be G0/G1-phase concentrated, S-phase concentrated, or G2/M-phase concentrated prior to 
being treated with B[a]P and the expression levels of CYP1A1, CYP1A2, CYP1B1, CDKN1A (P21WAF1/CIP1), BCL-2, and 
BAX levels were determined using quantitative real-time RT-PCR.  Levels of DNA damage were measured as DNA 
SSBs by the alkaline single cell-gel electrophoresis (comet) assay or as B[a]P-DNA adducts by 32P-postlabelling 
analysis.  B[a]P-induced up-regulation of CYP1A1 was >100-fold in S-phase concentrated cells, but in G0/G1-phase or 
G2/M-phase concentrated cultures up-regulation occurred to a significantly lower extent; in fact, CYP1A1 protein was 
undetectable in G0/G1-phase concentrated cultures by immunoblot analyses of whole-cell lysates with or without 24-h 
B[a]P treatment in contrast to a distinct band associated with S-phase concentrated cells.  Consistent with this, B[a]P-
treated S-phase concentrated cultures exhibited markedly up-regulated P21WAF1/CIP1, higher levels of dose-related 
increases in DNA SSBs, and increased DNA adduct levels presumably as a result of CYP1A1-mediated activation of 
B[a]P to B[a]P-diol-epoxide compared with the cultures enriched for the other cell cycle phases.  Whether cells cycle 
faster or are more quiescent in vitro may pre-determine susceptibility to activation of exogenous pro-carcinogens in 
short-term test systems and such findings have important implications when assessing risk to a particular target cell 
population in vivo. 
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P#18 
DNA adduct formation by benzo[a]pyrene in target and non-target mouse organs 
 
J. Zuo, C.S. Cooper, V.M. Arlt, and D.H. Phillips 
Section of Molecular Carcinogenesis, Institute of Cancer Research, Brookes Lawley Building, Sutton, Surrey SM2 
5NG, United Kingdom. 
  
DNA adduct formation is an early crucial event in the process of carcinogenesis by which many chemical carcinogens 
exert their biological effects. Correlations between DNA binding in target tissues and carcinogenic potency for some 
carcinogens are well established. However, it is more complex when considering target and non-target tissues and it is 
often not possible to predict accurately the target organs in humans from animal studies. This study has used the 32P-
postlabelling method to measure DNA adduct levels in Balb/c mice after exposure to the carcinogen benzo[a]pyrene 
(BaP) and the non-carcinogen benzo[e]pyrene (BeP) (125 mg/kg body weight/day by gavage). Target organs lung, 
spleen, forestomach and non-target organs liver, colon and glandular stomach were removed after 5 and 10 days of 
treatment, respectively. DNA adduct analysis showed that BaP forms DNA adducts time-dependently whereas BeP 
does not form adducts. Levels of BaP-DNA adducts were in the order spleen = liver > lung > colon = glandular stomach 
> forestomach. No significant difference in DNA adduct formation was seen between male and female mice. 
Collectively, DNA adduct levels were not significantly different between target and non-target organs. Our results 
suggest that events subsequent to DNA damage and mutations may be important in determining the organotropism of 
chemical carcinogens. Therefore, in future studies cDNA microarray will be used to identify critical changes in gene 
expression in mouse organs that may distinguish between target and non-target tissues for tumour formation. 
 
P#19 
Levels of the DNA adduct, N7-methyldeoxyguanosine, are associated with increased risk of failure of treatment 
of cervical intraepithelial neoplasia 
 
A.C. Povey1, K.L. Harrison1, C.J. Sutton3,  D. Mandal2, H. Kitchener4, and N.N. Acladious2 
1. Centre for Occupational and Environmental Health, University of Manchester, Manchester M13 9PL, UK; 2. 
Department of Genito-Urinary Medicine, Manchester Royal Infirmary, Manchester, UK; 3. Statistics Group, Faculty 
of Science, University of Central Lancashire, Preston PR1 2HE, UK; 4. Academic Unit of Obstetrics and 
Gynaecology, University of Manchester, UK. 
 
After conservative treatment of cervical intraepithelial neoplasia (CIN), the risk of invasive cervical cancer among these 
women is about five times greater than that among the general population of women. Treatment failure has been 
associated with numerous factors including persistent HPV infection and smoking. As tobacco specific nitrosamines are 
more prevalent in cervical mucus samples from smokers than non-smokers we have investigated whether exposure to 
these agents, as measured by N7-methyldeoxyguanosine (N7-MedG) levels in cervical DNA, are higher in those women 
who experience treatment failure than those who do not. 958 women attending for colposcopic examination after 
abnormal cervical smear test results were recruited into the cohort.  Information on demographic factors, smoking and 
other risk factors was obtained and a pre-treatment biopsy was taken and stored at –70oC. After follow-up, cases who 
had treatment failure of CIN within two years following treatment were identified (n=77) and matched to women with 
no treatment failure of CIN in this time period (controls, n=154). DNA was extracted from the pre-treatment biopsies 
and N7-MedG levels, were quantified as the ring-opened form of the base damage by a validated immunoslotblot assay. 
Sufficient DNA for N7-MedG analysis was extracted from 61 subjects corresponding to 20 matched case control pairs.  
N7-MedG was detected in cervical DNA with levels ranging from non-detected (<0.1µmol/mol dG) to 4.83 µmol/mol 
dG. N7-MedG levels were significantly higher in cases (geometric mean 0.99 µmol/mol dG) than controls 
(0.33µmol/mol dG; p=0.01). Log N7-MedG content, after adjustment for HPV status at time of treatment, was found to 
be significantly associated with increased risk of treatment failure (OR 5.74, 95% CI 1.05-31.23). The association 
between pre-treatment levels of DNA damage induced by methylating agents and subsequent treatment failure 
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P#20 
N7-methyldeoxyguanosine (N7-MedG) levels in DNA from colorectal adenoma cases and matched referents 
 
A.C. Povey1, N.P. Lees2,3, K.L. Harrison1, C.N. Hall2, and G.P. Margison3 
1. Centre for Occupational and Environmental Health, The University of Manchester, Oxford Rd, M13 9PL, UK; 2. 
Department of Gastrointestinal Surgery, Wythenshawe Hospital, Southmoor Road, Wythenshawe, Manchester, M23 
9LT, UK; 3. Cancer Research UK  Carcinogenesis Group, Paterson Institute for Cancer Research, Christie Hospital, 
Manchester, M20, 4BX, UK. 
 
The risk of developing colorectal cancer is influenced by dietary factors such as eating red meat but the mechanisms 
behind the variability in risk remain to be determined. Exposure to genotoxic carcinogens may be important as colon 
DNA contains damage induced by different carcinogens.  Exposure to alkylating agents may be one such environmental 
determinant of colorectal cancer risk. If alkylating agent exposure is important, it is likely that the critical period is 
during the growth of a small adenoma into a large adenoma as this is when a key mutational event, often linked to 
alkylating agent exposure, occurs (i.e. a GC→AT transition mutation in K-ras). We have therefore measured, as an 
indicator of alkylating agent exposure, N7-methyldeoxyguanosine (N7-MedG) levels in colorectal DNA, in the normal 
tissue of patients with and without colorectal adenomas. Biopsies of normal colorectal mucosa were collected during 
colonoscopy from 85 patients with histologically proven colorectal adenomas (cases) and 85 patients free of 
gastrointestinal neoplasia (referents) matched by age, gender and biopsy location.  N7-MedG levels were measured in 
DNA by a validated immunoslotblot procedure. N7-MedG levels were determined in DNA from 73 of the case-referent 
pairs. The majority of colorectal mucosal DNA samples contained detectable levels of N7-MedG (89% of cases and 
93% of referents). Levels ranged from <0.1 to 7.7 in cases and <0.1 to 4.4 fmoles/ µg DNA in referents. N7-MedG 
levels were not associated with gender, age, the size of the adenoma, or with current smoking status (data not shown).  
Cases and referents had similar DNA-N7-MeG levels. N7-MedG levels were not associated with the presence of an 
adenoma suggesting that methylating agents are unimportant in colorectal adenoma risk. However, as human exposure 




DNA adducts versus urinary metabolites of polycyclic aromatic hydrocarbons in healthy non-smoking females 
from Poland and Serbia 
 
C. Lundin1, G. Prochazka 1, D. Segerbäck1, A. Seidel2, J.Gromadzinska3, and R. Antic4 
1. Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden; 2. Biochemical Institute for 
Environmental Carcinogens, Grosshansdorf, Germany; 3. Nofer Institute of Occupational Medicine, Lodz, Poland; 
4. Academic Association for Research on Occupational and Public Health (AROPH), Zemun-Belgrade, Serbia. 
 
Beside occupational exposure, dietary intake seems to be the most important source of PAHs and the main objective of 
the project was to trace the origin of high background levels of PAH-type of DNA adducts found in certain non-
smoking individuals in the general population, while taking possible modulation by genetic factors and diet into 
consideration. The study population was 100 non-smoking women in each of the countries of Poland, Serbia and Italy. 
For all subjects, interviews about lifestyle and diet were performed, as well as genotyping of relevant detoxifying and 
DNA repair enzymes, determination of levels of PAH-DNA adducts and oxidative damages in DNA from white blood 
cells. Intake of PAHs was monitored by measurement of urinary PAH metabolites. DNA adduct levels were determined 
through sensitive dinucleotide/monophosphate version of the 32P-postlabelling assay followed by TLC separation of 5´-
labelled adducted monophosphates. Studies examining high exposure to PAH from smoking or occupation have shown 
that levels of urinary PAH metabolites as well as PAH-type of DNA adducts correlate with exposure to PAHs. However, 
contradictory results considering low exposure from air pollution have been found. Preliminary data from the women 
from Poland and Serbia showed that there was no correlation between levels of bulky DNA adducts and urinary PAH 
metabolites. The mean adduct level was statistically different between the two populations and correlated with the mean 
level of urinary PAH metabolites. Surprisingly, in both populations the 10 individuals with the highest adduct levels had 
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P#22 
Urinary 1-hydroxypyrene as a biomarker of polycyclic aromatic hydrocarbon exposure in the general 
population and correlation between 1-hydroxypyrene and white blood cell DNA adducts - Results of our 
literature survey 
 
K. Kovács, E. Győrffy, L. Anna, and B. Schoket 
Department of Molecular Environmental Epidemiology, National Institute of Environmental Health, Fodor József 
National Center for Public Health, Budapest, Hungary. 
 
Urinary 1-hydroxypyrene (1-OHPY) is a widely used surrogate marker for biomonitoring of complex polycyclic 
aromatic hydrocarbon (PAH) exposure of humans. In the present study our interest was on two specific areas of the 1-
OHPY literature, that is, 1-OHPY levels in the general population including comparison between adults and children, 
and the correlation between 1-OHPY and bulky DNA adduct level in white blood cells (WBC). The survey covers 32 
papers published between 1988 and 2006. Urinary 1-OHPY levels were in the range of 0.03 and 1.16 µmol/mol 
creatinine in adults and between 0.08 and 0.74 in children. Urban residence was associated with significantly higher 1-
OHPY level as compared to rural residence in both adults and children. 1-OHPY concentrations were higher in smokers 
than in non-smokers. ETS did not increase 1-OHPY concentration in children significantly. Significant age-dependent 
difference was observed recently by Huang et al (2006), in which 6-12 years old children had higher 1-OHPY levels 
than adolescents and adults. Females tended to have higher 1-OHPY levels than males, however, the effect was not 
significant. High dietary PAH exposure enhanced 1-OHPY excretion. The relationship between 1-OHPY and bulky 
DNA adducts was predominantly reported on occupational study populations. In some studies statistically significant 
correlation was found between 1-OHPY and WBC DNA adduct levels when the subjects were stratified for particular 
genetic polymorphisms, especially in coke oven workers with CYP1A1 462Val variant allele  (Pan et al, 1998),  in 
incinerator workers (Lee et al, 2002) and in aluminium plant workers (Schoket et al, 2001) with GSTM1 homozygous 
deletion.  The research project has been supported by the EU FP6 ECNIS NoE No. 513943. 
 
P#23 
Method development for 32P-postlabeling of N7-guanine DNA adducts 
 
M.G. Cornelius and D. Segerbäck 
Department of Biosciences and Nutrition at Novum, Karolinska Institute, Huddinge, Sweden. 
 
Detection and analysis of covalent DNA modifications is of great importance because a large body of evidence 
demonstrates that these DNA adducts are useful markers of carcinogen exposure, providing an integrated measurement 
of carcinogen intake, metabolic activation, and delivery to the DNA in target tissues. Monitoring DNA adducts also 
provides a means of investigating the correlation between occupational or environmental exposure in healthy 
individuals and cancer risk. The N7-position of guanine is the most nucleophilic position within the heterocyclic bases 
of DNA therefore the predominant reaction of many electrophilic compounds involves covalent bond formation at this 
site. These compounds include many structurally diverse alkylating agents like nitrosamines, epoxides and aflatoxins. 
The 32P-postlabeling method is based on enzymatic hydrolysis of DNA to deoxyribonucleoside-3’-monophosphates 
with micrococcal nuclease and spleen phosphodiesterase. N7-guamine adducts are then enriched by an anion exchange 
chromatography step and subsequently converted to 5’-32P-labeled 3’,5’-bisphosphates by enzymatic derivatization 
involving T4-polynucleotidkinase. Emphasis of the method development is placed on glycidamide, the ultimate 
genotoxic product of acrylamide. The neurotoxic and probable carcinogen compound acrylamide was first reported in 
cooked foods in 2002, including bread, french fries and breakfast cereals. In animal models, exposure to acrylamide 
leads to DNA damage and, at high doses, neurological and reproductive effects. The International Agency for Research 
on Cancer has classified acrylamide as “probably carcinogenic to humans”. Acrylamide is metabolized in vivo by 
CYP450 E1 to glycidamide which then forms DNA adducts at the N7 position of guanine and N1 position of adenine. 
Method development therefore includes the preparation of adduct standards, testing of postlabeling and enrichment 
conditions as well as development of different separation conditions using thin layer chromatography (TLC) and high 
performance liquid chromatography (HPLC). Preliminary results show that separation from normal nucleotides is 
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P#24 
Separation and detection of fluorescence labeled RNA modifications by capillary electrophoresis with laser-
induced fluorescence detection 
 
M.G. Cornelius, M. Wiessler, and H.H. Schmeiser  
German Cancer Research Center, Division of Molecular Toxicology, Germany. 
 
We investigated the separation and detection of the 5’-monophosphates of ribonucleosides selectively conjugated with 
BODIPY-FL-EDA (4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionyl ethylene diamine hydro-
chloride) at the 5’-phosphate group using capillary electrophoresis with laser-induced fluorescence detection (CE-LIF). 
BODIPY conjugates of the four common nucleoside-5’-monophosphates (guanosine-5’-monophosphate, adenosine-5’-
monophosphate, cytidine-5’-monophosphate and uracil-5’-monophosphate) were prepared and subjected to CE-LIF to 
serve as standard compounds for peak assignment and to develop separation conditions for the analysis of RNA. Also, 
two products arising from the deamination of the purinic nucleosides (inosine-5’-monophosphate and xanthine-5’-
monophosphate) were included in the above procedure. All BODIPY conjugates were detected and resolved by CE-LIF 
after digestion of RNA or oligonucleotides to 5’-monophosphates by nuclease P1 and fluorescence labeling without 
further purification step. Comparison with two previously developed assays with BODIPY-FL-EDA postlabeling for 
analysis of 2’-deoxynucleoside-3’- and -5’-monophosphates showed that all three versions were equally efficient and 
sensitive. Moreover, using our new assay we were able to analyze and quantify pseudouracil in samples from different 
types of RNA and RNA from different organisms. This indicates that fluorescence postlabeling of nucleoside-5’-
monophosphates after digestion of RNA with nuclease P1 has the potential to measure naturally occurring modified 
bases and modifications from exogenous sources in RNA.  
 
P#25 
Urinary excretion of ethenoadenine and ethenocytosine by smokers and nonsmokers 
 
G. Scherer1, G. Gilch1, H.W. Hagedorn1, and A.R. Tricker2 
1. ABF Analytisch-Biologisches Forschungslabor GmbH, Goethestr. 20, 80336 München, Germany; 2. Philip 
Morris Products S.A., PMI Research and Development, Neuchâtel, Switzerland. 
 
Tobacco smoking induces oxidative stress and lipid peroxidation resulting in the in vivo formation of promutagenic 
etheno DNA adducts. Etheno adducts are repaired by both base excision and nucleotide excision repair processes and 
excreted in urine as etheno-modified bases and nucleosides, respectively. It has been reported that smokers excrete 
elevated concentrations of 1,N6-ethenoadenine (etheno-A), 3-N4-ethenocytosine (etheno-C), 3-N4-ethenodeoxycytidine 
(etheno-dC), and 1,N2-ethenoguanine in urine. However, the relationship between urinary etheno adduct excretion and 
exposure to tobacco smoke has not been established. The excretion of both etheno-modified bases and nucleosides have 
the potential to serve as biomarkers of exposure to tobacco smoke and may also reflect oxidative stress and lipid 
peroxidation stemming from such exposure. An analytical method using gas chromatography with mass spectrometry 
(GC-MS) for the determination of etheno-C and etheno-A in human urine was developed and validated. This method 
was applied to the analysis of urine samples from 79 smokers and 24 nonsmokers collected under real-life conditions. 
Mean (± standard deviation) concentrations of etheno-C in urine were significantly increased in smokers compared to 
nonsmokers (0.35 ± 0.62 vs. 0.08 ± 0.08 nM; p < 0.05). Concentrations of etheno-A in urine, although higher in 
smokers compared to nonsmokers (0.57 ± 0.69 vs. 0.35 ± 0.20 nM), were not statistically significantly increased. 
Etheno-C excretion was also correlated with the molar sum of six urinary nicotine metabolites (r = 0.228; p = 0.054), 
but not with the number of cigarettes smoked per day (r = 0.137; p = 0.250), salivary cotinine (r = 0.201; p = 0.091), 
and CO in exhaled breath (r = 0.150; p = 0.208). Etheno-A excretion in urine was not correlated with any biomarker of 
smoking dose. We conclude that urinary etheno-C excretion may be a suitable biomarker for assessing smoking-related 
oxidative stress and lipid peroxidation. 
 
P#26 
Analysis of background DNA adducts in L5178Y mouse lymphoma cells by LC-MS/MS for the investigation of 
the biological significance of chemically-induced DNA damage 
 
A. Brink, B. Schulz, U. Lutz, W. Völkel, and W.K. Lutz 
Department of Toxicology, University of Würzburg, Versbacher Str. 9, D-97078 Würzburg, Germany. 
 
The biological significance of DNA adducts for mutation and cancer could be investigated on the basis of exposure-
related increments over background. For this purpose, analytical techniques are required for sensitive and specific 
quantification of background DNA adduct levels. Liquid-chromatography triple-quadrupole mass-spectrometry 
methods were developed and validated for the analysis of the 2’-deoxyribonucleoside adducts O6-methyl-2’-
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deoxyguanosine (O6-mdGuo), 8-oxo-2’-deoxyguanosine (8-oxodGuo), 1,N6-etheno-2’-deoxyadenosine (εdAdo) and for 
the purine adduct 7-methylguanine (7-mG). These adducts are formed both endogenously and exogenously by DNA 
methylation, direct oxidation of DNA, and reaction of DNA with lipid peroxidation products. O6-mdGuo was 
synthesized as standard, deuterated O6-[2H3]mdGuo was synthesized as internal standard. Using an on-line sample 
preparation with column switching, O6-mdGuo, 8-oxodGuo, and εdAdo could be determined simultaneously with 
minimum workup after enzymatic hydrolysis of DNA samples. The limits of quantification (LOQ) for O6-mdGuo, 8-
oxodGuo, and εdAdo were 24, 98, and 48 fmol on column (o.c.), respectively. The analysis showed linearity in the 
range 0.24 to 125 pmol/ml, 0.98 to 125 pmol/ml, and 0.48 to 62.5 pmol/ml for the three adducts, respectively. The inter-
day precision at 10-fold LOQ was 4.7% for O6-mdGuo, 13.4% for 8-oxodGuo, and 5.9% for εdAdo. 7-mG was 
analyzed in a separate LC-MS/MS assay after neutral thermal depurination from DNA. The LOQ was 30 fmol o.c., the 
dynamic range was 0.03 to 30 pmol o.c., the inter-day precision at 10-fold LOQ was 3.9%. The method was applied to 
DNA isolated from large batches of L5178Y untreated mouse lymphoma cells. In samples of 450 µg DNA, O6-mdGuo, 
8-oxodGuo, εdAdo and 7-mG showed levels of 38, 850, 300 and 1200 adducts per 109 normal nucleotides, respectively. 
The data can now be used as a baseline for dose-response relationships and correlations with other in vitro endpoints of 
genotoxicity and mutagenicity available for mouse lymphoma cells (refer to oral presentation by W.K. Lutz). 
 
P#27 
Organospecific upregulation of 8-oxo-7,8-dihydro-2′-deoxyguanosine 5′-triphosphate pyrophospho-hydrolase 
activity of mouse MTH1 protein by ionizing radiation-induced oxidative stress 
 
K. Bialkowski1, A. Szpila1, and K.S. Kasprzak2 
1. Department of Clinical Biochemistry, Collegium Medicum, Nicolaus Copernicus University, Karlowicza 24, 85-
092 Bydgoszcz, Poland; 2. Laboratory of Comparative Carcinogenesis, National Cancer Institute at Frederick, 
Building 538, Frederick, MD 21702-1201, USA. 
 
Mammalian MTH1 protein is an antimutagenic enzyme that prevents the incorporation of oxidatively modified purine 
nucleotides into nucleic acids. It decomposes a broad spectrum of 2’-deoxyribonucleoside and ribonucleoside 5’-
triphosphates (dNTPs and NTPs) to the corresponding nucleoside 5’-monophosphates and inorganic pyrophosphate. 
Although canonical dNTPs and NTPs are also substrates for MTH1 protein, the enzyme decomposes most specifically 
the miscoding products of oxidative damage to purine dNTPs and NTPs (e.g. 8-oxo-dGTP, 8-oxo-dATP, 2-OH-dATP, 
2-OH-ATP, 8-oxo-GTP) that may cause point mutations or transcription errors after the incorporation into DNA and 
RNA, respectively. There is a growing evidence for an overexpression of MTH1 gene in the cells/tissues that undergo 
oxidative stress. Therefore, the increased expression of MTH1 mRNA and MTH1 protein was proposed to be a new 
molecular marker of oxidative stress. To test whether oxidative stress can indeed affect MTH1, we investigated the 
influence of ionizing radiation (source of oxidative stress) on the MTH1 8-oxo-dGTPase activity in mouse organs. Male 
BL6 mice, 6-wk old, were subjected to 0, 10, 25, 50, and 100 cGy of 137Cs gamma-radiation, 100 cGy/min, given in a 
single dose per whole body, and killed 4, 8, and 24 hrs later (three mice per each dose/kill time combination). The 8-
oxo-dGTPase activity measurements were performed in 6 mouse organs. A clear induction of 8-oxo-dGTPase was 
noticed in mouse brains, testes, and kidneys, whereas lungs, hearts, and livers did not reveal any statistically significant 
effects of applied gamma radiation doses within 24 hours. Mouse brains, which demonstrated most dramatic 4.3-fold 
up-regulation of 8-oxo-dGTPase activity, were also shown to have significantly higher level of MTH1 protein as 
revealed by SDS-PAGE Western blot analysis. Our results indicate that comparative measurements of MTH1 8-oxo-
dGTPase activity might be used as a marker of oxidative stress in certain types of cells or tissues.  
 
P#28 
Development and statistical analysis of the mouse lymphoma thymidine kinase locus gene mutation assay for 
correlations between DNA adducts and mutant frequency 
 
B. Schulz1, A. Brink1, R.W. Lutz2, H. Stopper1, and W.K. Lutz1 
1. Department of Toxicology, University of Würzburg, Germany; 2. Seminar for Statistics, ETH Zürich, Switzerland. 
 
The L5178Y tk+/- mouse lymphoma assay is an established in vitro test for the induction of forward mutations. It is 
based on the selection of tk-/- mutants on the basis of their resistance to the toxic DNA precursor trifluorothymidine. The 
assay was adapted to large batches of cells, in order to get a sufficient amount of DNA for a concurrent adduct analysis 
by LC-MS/MS. Using this large scale, we (i) tested whether cleansing from background mutants resulted in improved 
sensitivity to low dose, (ii) defined the optimum time window for treatment after cleansing, and (iii) calculated 
confidence limits (CI) for the estimation of mutant frequencies based on the 96-well microtiter plate version. Results. (i) 
Cleansing clearly increased the sensitivity; treatment with 20 µM MMS immediately after cleansing resulted in a 
significant 2.9-fold increase in mutant frequency whereas no significant effect was observed in an uncleansed cell 
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population. (ii) The time window available for the investigation of small effects spanned 1 week after cleansing. 
Afterwards, the number of spontaneous mutants increased and sensitivity decreased. (iii) CI of the probable number of 
clones per well were calculated for all possible numbers of empty wells (EW). The minimum CI was seen for 21 EW. 
Based on 2000 plated cells per well, as recommended for mutation plates, the estimated cloning efficiency was [– ln 
(21/96)]/2000 = 0.000760, i.e. 760 per 106, with a 95% CI of 578 to 980 per 106. The ratio between the upper and the 
lower limits of the CI took values <1.7, <1.8, <1.9, and <2.0 for the ranges of EW 18-25, 8-44, 5-53, and 4-59, 
respectively. In order to minimize the statistical error, we consider it advisable to avoid large numbers of EW by 
adjusting the number of cells per plate. 
 
P#29 
Detection of phosphodiester adducts formed by the reaction of benzo[a]pyrene diol epoxide with 2′-
deoxynucleotides using collision induced dissociation tandem mass spectrometry. 
 
M. Gaskell, P.B. Farmer, and R. Singh 
Cancer Biomarkers and Prevention Group, Biocentre, University of Leicester, University Road, Leicester, LE1 7RH, 
UK. 
 
To date the potential of polycyclic aromatic hydrocarbons (PAHs) such as benzo[a]pyrene (B[a]P) to form phosphor-
triester adducts in DNA has not been clearly ascertained. Studies with alkylating agents have shown that phosphotriester 
adducts represent long lived biomarkers of exposure due to lack of efficient repair and it has been postulated that their 
formation may ultimately lead to adverse biological consequences, such as DNA strand breaks. PAHs are carcinogens 
that are ubiquitous environmental pollutants and are present in cigarette smoke, vehicle exhaust fumes as well as 
charbroiled food. B[a]P undergoes cytochrome P450 mediated metabolism in vivo resulting in the formation of 
benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide (B[a]PDE), the ultimate reactive species that reacts with nucleophilic 
sites in DNA. In this study we investigated the products formed following the in vitro reactions of B[a]PDE with 2′-
deoxynucleoside 3′-monophosphates of guanine, adenine, cytosine and thymine. The B[a]PDE plus 2′-deoxynucleotide 
reaction mixtures were purified using solid phase extraction (SPE) and subjected to HPLC with fluorescence detection. 
Fractions corresponding to reaction product peaks were collected and desalted using SPE. The purified reaction 
products were analysed for the presence of molecule ions corresponding to m/z 648, 632, 608 and 623 [M-H]- consistent 
with B[a]PDE adducted 2′-deoxynucleotides (either on the base or phosphate group) of guanine, adenine, cytosine and 
thymine, respectively, using liquid chromatography-negative electrospray ionization-tandem mass spectrometry (LC-
ESI-MS/MS) collision induced dissociation (CID). Reaction products were identified having CID product ion spectra 
characteristic of B[a]PDE adduct formation with the base of the 2′-deoxynucleotide. Product ions were observed at m/z 
452 (guanine), 436 (adenine) and 412 (cytosine) corresponding to [B[a]P-triol+base-H]-, resulting from cleavage of the 
glycosidic bond between the 2′-deoxyribose and the B[a]PDE adducted base. Further reaction products were identified 
having unique CID product ion spectra characteristic of B[a]PDE adduct formation with the phosphate group of the 2′-
deoxynucleotide. The presence of product ions at m/z 399 and 497 was observed for all four 2′-deoxynucleotides, 
corresponding to [(B[a]P-triol+phosphate)-H]- and [(2′-deoxyribose+phosphate+B[a]P-triol)-H]-, respectively. The 
absence of product ions in the spectra corresponding to B[a]PDE adducted bases provided further confirmation of the 
formation of phosphodiester adducts. In conclusion this work provides the first direct evidence for the formation of 
phosphodiester adducts by B[a]PDE and it is anticipated that similar reactions occur in DNA resulting in the formation 
of phosphotriester adducts. 
 
P#30 
Investigations on the mutation signature of 3-nitrobenzanthrone in the human p53 sequence 
 
J. vom Brocke and H.H. Schmeiser 
Division of Molecular Toxicology, German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, 
Germany. 
 
To test hypotheses on the origins of p53 mutations in human tumors, novel strategies are needed for generating 
mutation spectra experimentally. Recently, an assay employing Hupki (Human p53 knock-in) mouse embryonic 
fibroblasts (HUFs) has been developed. Utilizing this assay, we examined p53 mutations induced by 3-nitro-
benzanthrone (3-NBA), a carcinogen and environmental pollutant. Seven immortalized cultures (cell lines) from 26 
HUF primary cultures exposed at passage 1 for 48 hrs to 7.5 µM 3-NBA harboured mutations in the human DNA 
binding domain sequence of the Hupki p53 tumor suppressor gene or its splice sites. DNA was isolated, amplified and 
sequenced via the dye-terminator method to reveal manifest point mutations in the coding region of exons 4–9. 
Preliminary results indicate mostly A to G transitions, next to mutations of the splice site preceding exon 8. The 
mutations found at codons 205, 259 and the splice site have not been observed in previous experiments. Apart from 
point mutations in the coding region (e.g. p53), a tumor suppressor can be inactivated through hypermethylation of the 
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promoter region, which silences the gene (e.g. RASSF1A). This often coincides with genome-wide DNA hypo-
methylation. Thus, a second focus is on the DNA methylation status of the HUF cell-lines. To measure the degree of 
methylation, DNA was hydrolyzed to 3’-nucleotides, derivatized with a fluorescent dye and analyzed through micellary 
electrokinetic capillary chromatography with laser-induced fluorescence detection (CE-LIF). The degree of DNA 
methylation in HUF cell lines that were mutant in p53 was significantly lower (3.8%) than that of primary cultures 
(4.0%, p<0.001), while that of cell lines wild-type in p53 was even lower (3.6%, p<0.001). 
 
P#31 
Enzymes and conditions used for DNA hydrolysis affect the release of propano adducts: Comparison of LC-
MS/MS using column switching with 32P-postlabeling methods 
 
P. Wanek, A. Brink, and E. Eder 
Department of Toxicology, University of Würzburg, Germany. 
 
4-Hydroxynonenal-2’deoxyguanosine (HNE-dGuo) propano adducts are promutagenic DNA lesions originating from 
free radical-induced lipid peroxidation of polyunsaturated fatty acids. A sensitive LC-MS/MS method was developed to 
measure propano adducts, using online sample clean-up by column switching coupled with tandem mass spectrometry. 
Although high amounts of DNA (250 µg) were hydrolyzed and injected we were not able to confirm the levels of HNE-
dGuo previously estimated by 32P-postlabeling. We hypothesized that incomplete DNA hydrolysis to 2’-
deoxyribonucleosides by the nuclease P1 (NP1) and alkaline phosphatase (AP) digestion system used might be 
responsible. Therefore, we investigated the effect of different DNA digestion systems on the release of HNE-dGuo and 
the normal 2’-deoxyribonucleosides. The enzymes tested were DNAse I, Snake Venom Phosphodiesterase (SVPDE), 
Phosphodiesterase from Bovine Spleen (SPDE), Micrococcal Nuclease (MN) and NP1 to release the 3`- or the 5`-
monophosphatenucleotides followed by a subsequent treatment with alkaline phosphatase (AP). Results:  Clear 
differences in the amount of HNE-dGuo detected were observed with the various digestion systems. No signal for 
HNE-dGuo could be found with the originally used NP1 hydrolysis system and the highest signal could be detected 
with a DNAse I+SVPDE hydrolysis system, whereas the amounts of the normal 2`-deoxyribonucleosides released from 
DNA were similar in all DNA digestion systems tested. Discussion: Combination of DNAse I+SVPDE+AP was the 
most effective DNA hydrolysis system for liberation of HNE-dGuo from DNA. The considerably smaller amounts of 
HNE-dGuo obtained with MN+SPDE+AP may indicate that the levels detected with our 32P-postlabeling method were 
underestimated. Further studies must prove if this applies to other propano adducts as well. 
 
P#32 
European Standards Committee on Urinary (DNA) Lesion Analysis (ESCULA): Towards consensus for the 
measurement of urinary 8-oxo-7,8-dihydro-2’-deoxyguanosine 
 
M.S. Cooke1, R. Olinski2, S. Loft3, R. Singh1, P. Farmer1, and M.D. Evans1  
1. Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, UK; 2. Department of 
Clinical Biochemistry, Collegium Medicum, Nicolaus Copernicus University Bydgoszcz, Poland; 3. Department of 
Occupational & Environmental Health, Institute of Public Health, Panum, Øster Farimagsgade 5, DK 1014 K, 
Copenhagen, Denmark. 
 
There is growing evidence that, rather than simply being a non-invasive marker of whole body oxidative stress, 
measurement of urinary lesions, such as 8-oxo-7,8-dihydro-2’-deoxyguanosine (8-oxodG), may, to some extent, reflect 
the repair of oxidised DNA and deoxynucleotides, although their precise provenance is far from clear.  A discrepancy in 
basal urinary 8-oxodG levels has been noted when comparing chromatographic techniques (e.g. GC/MS following prior 
HPLC pre-purification, or LC-MS/MS, or LC-EC) with ELISA, although all techniques have been shown to 
discriminate between diseased and healthy subjects, and possess good within-technique agreement.  ELISA has 
received widespread use, and is clearly amenable to the greatest number of laboratories, however, this discrepancy 
continues to raise questions regarding its utility.  Understanding the basis of this discrepancy will aid our understanding 
of the significance of urinary lesions.  Furthermore, performing inter-laboratory validation of assays for urinary 8-
oxodG measurement would provide robust methods for widespread dissemination and application.  Hitherto, this has 
been performed in a limited fashion, and the discrepancies remain undressed.  Finally, there is growing clinical interest 
in the measurement of urinary 8-oxodG, as a means to determine the role of oxidative stress in disease, and evaluate 
intervention strategies.  As with other clinical parameters, a reference range must first be determined.  ECNIS support 
has been provided, enabling the formation of the European Standards Committee on Urinary (DNA) Lesion Analysis 
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P#33 
Genotoxicity of urban particulate matter is due to both organic and inorganic components 
 
M. Routledge1, J. Lingard2, A. Tomlin2, E. Smith1, C. Wild1, and K. Healey1 
1.Molecular Epidemiology Unit, Leeds Institute for Genetics Health & Therapeutics, University of Leeds, Leeds, 
UK; 2.Energy & Resources Research Institute, University of Leeds, Leeds, UK. 
 
We have examined the genotoxicity of urban particulate matter (UPM) using the comet assay, 32P-postlabelling assay 
and supF mutation assay. Human lung epithelial A549 cells were exposed to size segregated UPM and DNA damage 
assessed by the comet assay. 32P-postlabelling assay was used to confirm that DNA adducts were induced in the treated 
cells. In the comet assay, DNA strand breaks increased with exposure to decreasing size of UPM, with maximum 
damage induced by particles smaller than 2.5 µm diameter. About 75% of this DNA damaging ability was retained by 
an organic extract of the UPM. Using the plasmid strand break assay we demonstrated that free radicals were also 
generated by the UPM. To investigate the mutagenicity of this free radical generating capacity, we exposed pSP189 
plasmid to the UPM and examined mutations in the supF assay. The mutation frequency induced by 1 µg/µl UPM was 
4.99 mutants per 104 colonies, compared to a background mutation frequency of 0.35 mutants per 104 colonies. The 
UPM induced mutation frequency was reduced to 0.84 and 1.48 mutants per 104 colonies by addition of 1 mM mannitol 
or 1mM EDTA, respectively. Of the base substitution mutations, 88% where at GC pairs, with twice as many 
transversions as transitions. The types of mutations induced, the reduction of mutagenicity by the inclusion of the free 
radical scavenger, mannitol, or the metal chelator, EDTA, and the sequence context of the induced mutations all support 
the conclusion that the majority of mutations were induced by reactive oxygen species generated by metal ions present 
in the UPM. Taken together the results of our studies highlight the fact that both organic chemical carcinogens and 
metal ions contribute to the potential genotoxicity of UPM. 
 
P#34 
Smoking-related bulky DNA adducts and TP53 mutations in lung adenocarcinoma and squamous cell carcinoma 
 
L. Anna1, E. Győrffy1, K. Kovács1, Z. Győri2, J. Segesdi2, J. Minárovits2, I. Soltész3, Sz. Kostič3, A. Csekeő3, R. 
Holmila4, K. Husgafvel-Pursiainen4, and B. Schoket1 
1. Fodor József  National Center for Public Health, Hungary; 2. National Center for Epidemiology; 3. Korányi 
National Institute of Pulmonology, Hungary; 4. Finnish Institute of Occupational Health, Finland. 
 
TP53 tumour suppressor gene mutations are common genetic alterations in human lung cancer. TP53 has a regulatory 
role in various cellular mechanisms including cell-cycle control, DNA repair and apoptosis. The aim of the project was 
to study the associations between the levels of smoking-derived aromatic DNA adducts, mutations of TP53, smoking 
status and histological type of lung cancer in a Hungarian study population. Tumour and normal lung tissue samples 
were available from 104 adenocarcinoma and squamous cell carcinoma patients, who underwent lung resection. 
Aromatic DNA adducts were determined by 32P-postlabelling. TP53 mutations were detected in the tumour tissue in 
exons 5 to 9 and 11, and mutations were sequenced. Smokers had statistically significantly higher level of DNA adducts 
than non-smokers, and normal lung tissues had two-fold higher DNA adduct level than tumour tissues. There was a 
statistically significant correlation between DNA adduct levels of the normal and the tumour tissue (r=0.64, p<0.0001).  
Among smokers, TP53 mutation carriers had similar DNA adduct level as the subjects with wildtype TP53, whereas in 
non-smokers mutation was associated with higher DNA adduct level (p=0.076), especially with mutation on exon 5 
(p=0.01). G->T mutation was detected exclusively with smokers, and G->A mutation was predominant with non-
smokers.  Slightly enhanced DNA adduct level was observed with G->A mutation as compared to the wildtype (p=0.18). 
No conclusive difference was seen in DNA adduct levels according to the histological type. The results suggest that 
association between TP53 mutation and aromatic DNA adduct level may be more apparent in non-smokers. 
 
Acknowledgements: The research was partly supported by OTKA T034616, Finnish-Hungarian S&T SF-02/01 and SF-
14/03. This work was also partly supported by ECNIS (Environmental Cancer Risk, Nutrition and Individual 
Susceptibility), a network of excellence operating within the European Union 6th Framework Program, Priority 5: "Food 
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P#35 
Kinetic of induction and disappearance of DNA-strandbreaks and mutations of different alkylating agents: 3-
nitrosooxazolidine-2-one (NOZ-2), 3-nitrosooxazolidin-5-one (NOZ-5) and glycidamide using comet-assay and 
hPRT-gene-mutation-assay in V79-cells 
 
S. Thielen1, M. Baum1, M. Hoffmann1, R. N. Loeppky2, S. Michael1, and G. Eisenbrand1 
1. University of Kaiserslautern, Department of Chemistry, Division of Food Chemistry and Environmental 
Toxicology, D-67663 Kaiserslautern, Germany; 2. University of Missouri, Department of Chemistry, Columbia, 
Missouri 65211, USA. 
 
Genotoxic N-Nitrosooxazolidinones have been reported to be generated from nitrosated amino acids in the presence of 
dietary aldehydes. These compounds can rapidly hydrolyse, generating highly reactive diazonium-ions supposed to 
covalently interact with nucleophilic centers in DNA. The induction and disappearance kinetics of DNA-strandbreaks 
was studied with the putative hydroxyethylating NOZ-2 and its carboxy-methylating/methylating analogue NOZ-5. 
Glycidamide (GA), a preferentially N7-guanine-alkylating agent, was tested in comparison. Mutagenicity was 
determined by the hPRT-gene-mutation-assay. NOZ-2 strongly induced DNA-strandbreaks (SSB) already after 15’ 
incubation (≥3µM). Additional treatment with the DNA-repair enzyme formamido-pyrimidine-DNA-glycosylase (FPG) 
did not substantially increase DNA-strandbreaks. In contrast, GA and NOZ-5 were only marginally active without FPG-
treatment (≥300µM), but FPG-treatment elevated the response significantly (≥10µM). Moreover, whilst NOZ’s induced 
DNA-strandbreaks very fast (15’ incubation), GA reacted much slower (≥1h). Within 8h, GA-induced DNA-
strandbreaks (300µM) disappeared nearly completely. In contrast, within the same time-interval the NOZ-2-induced 
DNA-lesions (30µM) were persistent. Both NOZ’s were strongly mutagenic inducing significant hPRT-mutations 
already at ≥10µM. GA became significantly mutagenic only at about 80-fold higher concentrations.  In terms of DNA-
lesions, NOZ-2 is expected to hydroxyethylate, NOZ-5 to carboxymethylate/methylate DNA at various nucleophilic 
centers, including O6 and N7 of guanine. Predominantly however, alkylation at the phosphodiester groups of the DNA-
backbone is to be expected. Since V79 cells are repair-deficient concerning O6-alkyltransferase, the strong hPRT-
mutagenicity of NOZ’s might be ascribed to proportionate O6-alkylation and to further more persistent lesions. Given, 
that N7-adducts are subject to FPG-repair, the strong comet-signal-enhancement by FPG for NOZ-5 finds an 
explanation. In contrast, the FPG-effect on the NOZ-2-induced comet-signal is small, most probably because phosphate 
group hydroxyethylation triggers spontaneous SSB-induction. At variance to NOZ-2 however, phosphotriesters 
generated by NOZ-5 are not supposed to give rise to spontaneous SSB, thus allowing the FPG-effect to become 
detectable. In contrast to NOZ-induced SSB, GA-induced SSB are effectively removed within 8h in V79 cells which 
might explain in part the rather weak hPRT-mutagenicity.  
 
P#36 
DNA adduct formation capacity and induction of oxidative stress by the carcinogenic urban air pollutant 3-
nitrobenzanthrone and its abundant isomer 2-nitrobenzanthrone, measured in vitro and in vivo 
 
E. Nagy1, S. Adachi2, T. Takamura-Enya3, M. Zeisig1, and L. Möller1 
1. Karoliska Institutet, Department of Bioscience and Nutrition at Novum, Huddinge, Sweden; 2. Sagami Women’s 
University, Department of Public Health, Kanagawa, Sagamihara, Japan; 3. National Cancer Center Research 
Institute, Cancer Prevention Basic Research Project, Chuo-ku, Tokyo, Japan. 
 
Background: The carcinogenic vehicle emission product 3-nitrobenzanthrone (3-NBA) is known to rearrange in the 
atmosphere to the isomer 2-nitrobenzanthrone (2-NBA), hence 2-NBA but it exists in 70-fold higher concentration in 
ambient air. 
Methods: The genotoxicity of 2-NBA and 3-NBA was studied both in vitro (A549 and human hepatic tumour cells 
HepG2) and in vivo (F344 rat) models, using the 32P-HPLC and the Single Cell Gel Electrophoresis (Comet assay) 
method. In vitro, also the parent compound benzanthrone (BA) and the metabolite 3-aminobenzanthrone (3-ABA) were 
evaluated. 
Results in vitro: 3-NBA gave highest levels of DNA adducts in the two cell lines, but significantly higher in HepG2 (∼ 
500 adducts/108 normal nucleotides (NN)) compared to A549 (∼ 300 adducts/108 NN), whereas 2-NBA formed about 
1/3 and 1/10 of the DNA adduct amount in A549 and HepG2 cells, respectively. 3-ABA formed significantly higher 
DNA adduct level only in the A549 cells, whereas BA did not give rise to any detectable amounts of DNA adducts. The 
DNA adduct patterns from 3-NBA were similar in vitro and in vivo, but differed somewhat for 2-NBA. The oxidative 
stress induced by BA was almost as high as what was observed for 3-NBA and 3-ABA in both cell lines, whereas 2-
NBA induced lowest level of oxidative stress. 
Results in vivo: The oxidative stress and DNA adduct level, in whole blood, was significantly increased by 3-NBA but 
not by 2-NBA. 3-NBA also formed the highest levels of DNA adducts in the nine tissues examined, compared to 2-
NBA. While DNA adduct level in the 3-NBA exposed animals reached a peak around 1 and 2 days post instillation, 2-
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NBA treated animals showed a tendency towards a continuing increase at the end of the study. This raises the question 
whether 2-NBA can be stored longer in the body compared to 3-NBA, or if it has the potential to bioaccumulate and 
thereby pose a greater and more long-term threat to health. 
 
P#37 
Inhibition of nucleotide excision repair by neutrophils: role of myeloperoxidase 
 
N. Güngör, R.W.L. Godschalk, F.J. Van Schooten, and A.M. Knaapen  
Nutrition and Toxicology Research Institute Maastricht (NUTRIM), Department of Health Risk Analysis and 
Toxicology, Maastricht University, 6200 MD, PO Box 616, Maastricht, The Netherlands. 
 
Inflammation has been recognized as an important factor in cancer development. However, the biological processes 
underlying this relationship have not been fully defined. In the lung, the influx of polymorphonuclear neutrophils 
(PMN) is considered as a specific etiological factor linking inflammation with carcinogenesis. More specifically, 
neutrophils are implicated in pulmonary carcinogenesis through their capacity to accelerate the metabolism of inhaled 
chemical carcinogens, causing enhanced formation of pro-mutagenic bulky DNA-adducts. We aimed to investigate the 
effect of neutrophils on the DNA repair processes involved in the removal of such adducts. Specifically, we tested the 
hypothesis that neutrophils are potent inhibitors of nucleotide excision repair (NER). Alveolar epithelial cells (A549) 
were co-incubated with PMA-activated human neutrophils. Phenotypical assessment of NER capacity in the exposed 
A549 cells was performed using a modified comet-assay. The co-incubated epithelial cells showed a PMN dose-
dependent reduction of NER capacity. Moreover, we found that addition of the specific myeloperoxidase (MPO) 
inhibitor 4-ABAH abrogates NER inhibition by PMN. In further experiments we showed that the MPO-product HOCl 
also dose-dependently and persistently (24h) reduced DNA repair capacity in the A549 cells, indicating that NER 
inhibition by PMN is mediated by MPO-dependent formation of HOCl. Importantly, these effects were observed in the 
absence of cytotoxicity or loss of cellular ATP. Besides, no down-regulation of NER-relevant genes (ERCC-1, XPA, 
XPC, XPF, XPC) was observed. Further preliminary data suggest a role of protein modification in the inhibition of 
NER by HOCl. We finally showed by using 32P-postlabeling that HOCl-induced inhibition of NER was associated with 
a delayed removal of DNA-adducts in benzo[a]pyrene-exposed A549 cells. Our data show that neutrophils are potent 
inhibitors of nucleotide excision repair through MPO-mediated formation of HOCl. Generally, these observations may 
provide a further biological explanation for the observed association between neutrophilic inflammation and lung 
cancer risk in smokers. 
 
P#38 
Determination of the DNA methylation level: An increase in sample throughput by an optimised sample 
preparation 
 
M. Thiemann1, R. Schiewek1, M. Wirtz1, H.H. Schmeiser2, and O.J. Schmitz1 
1. Department of Analytical Chemistry, University of Wuppertal, Gauss Str. 20, 42119 Wuppertal, Germany; and 2. 
Department of Molecular Toxicology, German Cancer Research Centre Heidelberg, INF 280, 69120 Heidelberg, 
Germany. 
 
The epigenetic code, i.e. the methylation of cytosines, various histone modifications and DNA-binding proteins, is, 
unlike the genetic code, always being rewritten and erased. Epigenetic mistakes are involved not only in mutations in 
the genotype, but also in the development of abnormalities, cancer and other diseases. Using a capillary electrophoretic 
method we have previously shown, that the genomic methylation level can be determined very exactly. In the present 
work, this method was applied to study the degree of methylation in tissue samples of rats that had been treated with 3-
NBA. In the various organs of treated animals, the degree of methylation was found to be different from those of 
control animals. For coping with the increased quantity of samples in an adequate time, we also present here a sample 
preparation that eliminates the surplus of fluorescence marker and carbodiimide used for the coupling reaction. With 
this method, sequences of up to 120 measurements can be carried out, which increased the sample throughput from 75 
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P#39 
Paternal exposures to benzo[a]pyrene and genetic risk in their offspring 
 
N. Verhofstad1, R. Godschalk1, J. van Benthem2, H. van Steeg2, and F.J. van Schooten1 
1. Department of Health Risk Analysis and Toxicology, University of Maastricht, Maastricht, The Netherlands 2. 
Laboratory of Toxicology, Pathology and Genetics, National Institute for Public Health and the Environment 
(RIVM), Bilthoven, The Netherlands. 
 
Polycyclic aromatic hydrocarbons (PAHs), like benzo[a]pyrene (B[a]P), are well known environmental and 
occupational pollutants. Subjects exposed to PAHs were found to be at risk to develop malignancies. Although PAHs 
induce without any doubt gene mutations in somatic cells and consequently somatic tumors, their role in germ cell gene 
mutation induction is largely unknown. No relevant human or limited laboratory animal studies on male reproductive 
effects have been done so far. Still though, it is likely to assume that paternal exposure to mutagenic chemicals may 
increase health risks in offspring individuals owing to induction of mutations in the DNA of gametes. Children may 
inherit gene mutations, which were induced upon exposure to DNA damaging agents during different stages of 
spermatogenesis. Next, there is some human evidence demonstrating that paternal exposure to PAHs causes gene 
mutations in sperm DNA, and animal studies using B[a]P as a challenging seem to support these human data. However, 
there is also evidence that germ cells are protected from paternal exposures by a complex network of molecular defence 
mechanisms. As such it is still far from clear yet what the human risk is for PAH-induced germ cell mutagenesis. 
Therefore, it is our intension to investigate reproductive effects of low dose pre-conceptional B[a]P exposure to further 
establish potential health risks in offspring. To be successful more sensitive methods are required (like DNA repair 




Analytical characterization of azanucleosides as novel chemotherapeutic agents 
 
D. Stach, F. Schmitges, and F. Lyko 
Division of Epigenetics, German Cancer Research Center, Im Neuenheimer Feld 580, 69120 Heidelberg, Germany. 
 
Epigenetic therapy plays an increasingly important role in the treatment of leukemia and other forms of cancer. 
Currently, the nucleoside DNA methyltransferase inhibitors Decitabine (5-aza-2‘-deoxycytidine) and Vidaza (5-
azacytidine) represent the most advanced drugs. However, their physico-chemical characteristics and their incorporation 
rates into DNA have been poorly characterized. We are using capillary electrophoresis (CE) to analyze azanucleosides 
in various experimental contexts. In a first series of experiments, we have determined the stability of both Decitabine 
and Vidaza in their standard application concentrations. This revealed an unexpected half-life time of several hours up 
to 4 days at clinically relevant temperatures (20°C and 37°C). This finding should allow the application of the drug in a 
more patient-friendly way. Secondly, we took a closer look on the demethylating kinetics of the two methyltransferase 
inhibitors. The result was an interesting difference between Decitabine and Vidaza in the demethylating effect over time. 
A synthesis of a 3‘-phosphate standard of 5-aza-2‘-deoxycytidine was performed to unambiguously identify the 
compound peak during CE analysis of complex DNA samples and to optimise separation conditions. This will allow the 
identification of 5-aza-2‘-deoxycytidine 3‘-phosphate as a distinct signal among other genomic nucleotides. The aim 
will be to analyse DNA samples from drug treated cell lines and finally tumour samples from patients undergoing 
epigenetic therapy with regard to determine drug incorporation rates into genomic DNA and to potentially optimise 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































List of Participants 
 50
No     Name Institution Division Town, Country
1 Dr. Antonio Agudo Catalan Institute of Oncology Unit of Epidemiology L’Hospitalet de Llobregat, Spain 
2 Dr. Allessandra Allione Institute for Scientific Interchange Foundation Molecular Epidemiology Laboratory Torino, Italy 
3 Ms. Livia Anna National Institute of Environmental Health Jozsef Fodor National Center for Public Health Budapest, Hungary 
4 Dr. Volker Manfred Arlt Institute of Cancer Research Section of Molecular Carcinogenesis Sutton, UK 
5 Mrs. Chimgee Baasanjav German Institute for Human Nutrition Department of Toxicology Berlin, Germany 
6 Ms. Tamara Bakuradze Technical University of Kaiserslautern Division of Food Chemistry & Environmental Toxicology Kaiserslautern, Germany 
7 Dr. Silvia Balbo International Agency for Research on Cancer Gene-Environment Epidemiology Group Lyon, France 
8 Dr. Matthias Baum Technical University of Kaiserslautern Division of Food Chemistry & Environmental Toxicology Kaiserslautern, Germany 
9 Prof. Helmut Bartsch German Cancer Research Center Division of Toxicology and Cancer Risk Factors Heidelberg, Germany 
10 Dr. Federick Beland FDA National Center for Toxicological Research Division of Biochemistry Jefferson, AR, USA 
11 Mr. Phillip Bellion Technical University of Kaiserslautern Division of Food Chemistry & Environmental Toxicology Kaiserslautern, Germany 
12 Mr. Franz Berger Technical University of Kaiserslautern Division of Food Chemistry & Environmental Toxicology Kaiserslautern, Germany 
13 Dr. Karol Bialkowski Nicolaus Copernicus University Department of Clinical Biochemistry Bydgoszcz, Poland  
14 Dr. Christian Bieler Consultant Hedwig-Jochmus-St. 12 Heidelberg, Germany 
15 Dr. Paolo Boffetta International Agency for Research on Cancer Gene-Environment Epidemiology Group Lyon, France 
16 Dr. Maria Botsivali National Hellenic Research Foundation Institute of Biological Research and Biotechnology Athens, Greece 
17 Mr. Andreas Brink University of Würzburg Department of Toxicology Würzburg, Germany 
18 Dr. Thomas Broschard Merck KGaA Institute of Toxicology Darmstadt, Germany 
19 Dr. Karen Brown University of Leicester Department of Cancer Studies and Molecular Medicine Leicester, UK 
20 Prof. Sabin Cinca Institute of Oncology  Bucharest, Romania 
21 Dr. Marcus Cooke University of Leicester Department of Cancer Studies and Department of Genetics Leicester, UK 
22 Dr. Michael Cornelius Karolinska Institute  Department for Bioscience at Novum Stockholm, Sweden  
23 Mrs. Claudia Donath German Institute for Human Nutrition Department of Toxicology Berlin, Germany 
24 Mr. Matthias Dürr University of Halle-Wittenberg Institute of Hygiene Halle, Germany 
25 Ms. Agnieszka Dyrcz Gdansk University of Technology Department of Pharmaceutical Technology and 
Biochemistry 
Gdansk, Poland 
26 Mr. Tomasz Dziaman Nicolaus Copernicus University Department of Clinical Biochemistry   Bydgoszcz, Poland
27 Prof. Gerhard Eisenbrand University of Kaiserlautern Department of Food Chemistry and Environmental 
Toxicology 
Germany, Germany 
28 Prof. Erwin Eder University of Würzburg Department of Toxicology Würzburg, Germany 
29 Dr. Jean Emeny University of Leicester Cancer Biomarkers and Prevention Group Leicester, UK 
30 Dr. Mark Evans University of Leicester Department of Cancer Studies and Department of Genetics Leicester, UK 
31 Prof. Peter Farmer University of Leicester Cancer Biomarkers and Prevention Group Leicester, UK 
32 Dr. Virginie Faucet-Marquis ENSAT Laboratoire de Génie Chimique Auzeville-Tolosane, France 
33 Ms. Julia Feld Technical University of Kaiserslautern Division of Food Chemistry & Environmental Toxicology Kaiserslautern, Germany 
34 Dr. Norbert Frank German Cancer Research Center Division of Toxicology and Cancer Risk Factors Heidelberg, Germany 
35 Dr. Charlotta Fred AstraZeneca R&D Södertälje Department of Genetic and Cellular Toxicology  Södertälje, Sweden
36 Dr. Eva Frei German Cancer Research Center Division of Molecular Toxicology Heidelberg, Germany 
37 Dr. Daniel Gackowski Nicolaus Copernicus University Department of Clinical Biochemistry   Bydgoszcz, Poland
List of Participants 
 51
38 Dr. Goncalo Gamboa da Costa Institute of Cancer Research Section of Molecular Carcinogenesis Sutton, UK 
39 Dr. Clarissa Gerhäuser German Cancer Research Center Division of Toxicology and Cancer Risk Factors Heidelberg, Germany 
40 Dr. Panagiotis Georgiadis National Hellenic Research Foundation Institute of Biological Research and Biotechnology Athens, Greece 
41 Ms. Nejla Güngör University of Maastricht Department of Health Risk Analysis and Toxicology Maastricht, The Netherlands 
42 Prof. Hansrudi Glatt German Institute for Human Nutrition Department of Toxicology Berlin, Germany 
43 Dr. Roger Godschalk University of Maastricht Department of Health Risk Analysis and Toxicology Maastricht, The Netherlands 
44 Dr. Hazel Greetham University of Newcastle upon Tyne Human Nutrition Research Centre Newcastle upon Tyne, UK 
45 Dr. Claas Gronewold Kao Professional Salon Services GmbH  Darmstadt, Germany 
46 Dr. Arthur Grollman State University of New York at Stony Brook Department of Pharmacological Sciences Stony Brook, NY, USA 
47 Ms. Jolanta Guz Nicolaus Copernicus University Department of Clinical Biochemistry   Bydgoszcz, Poland
48 Ms Uta Herbst Federal Office for Consumer Protection and Food 
Safety 
 Berlin, Germany  
49 Prof. Kari Hemminki German Cancer Research Center Division of Molecular Genetic Epidemiology Heidelberg, Germany 
50 Dr. Monica Hollstein German Cancer Research Center Division of Genetic Alterations in Carcinogenesis Heidelberg, Germany 
51 Ms. Birgit Höft German Cancer Research Center Division of Clinical Epidemiology Heidelberg, Germany 
52 Dr. Farhad Islami International Agency for Research on Cancer Gene-Environment Epidemiology Group Lyon, France 
53 Dr. Christine Janzowski Technical University of Kaiserslautern Division of Food Chemistry & Environmental Toxicology Kaiserslautern, Germany 
54 Mr. Marco Kellert University of Würzburg Department of Toxicology Würzburg, Germany 
55 Dr. Arab Khelifa German Cancer Research Center Division of Toxicology and Cancer Risk Factors Heidelberg, Germany 
56 Dr. Christian Kliem German Cancer Research Center Division of Molecular Toxicology Heidelberg, Germany 
57 Dr. Ad Knaapen University of Maastricht Department of Health Risk Analysis and Toxicology Maastricht, The Netherlands 
58 Ms. Katalin Kovacs National Institute of Environmental Health Jozsef Fodor National Center for Public Health Budapest, Hungary 
59 Mrs. Brita Krämer-Bautz Bayer HealthCare AG Department of Toxicology Wuppertal, Germany 
60 Dr. Gunter G.C. Kuhnle MRC Dunn Nutrition Unit Diet & Cancer Group Cambridge, UK 
61 Dr. Soterios Kyrtopoulos National Hellenic Research Foundation Institute of Biological Research and Biotechnology Athens, Greece 
62 Dr. Robert Landsiedel BASF AG GV/TB Z 470 Ludwigshafen, Germany 
63 Dr. Rachel Le Pla University of Leicester Cancer Biomarkers and Prevention Group Leicester, UK 
64 Mrs. Joanna Lewandoska 
 
Gdansk University of Technology Department of Pharmaceutical Technology and 
Biochemistry 
Gdansk, Poland 
65 PD Dr. Jakob Linseisen German Cancer Research Center Division of Clinical Epidemiology Heidelberg, Germany 
66 Dr. Cecilia Lundin Karolinska Institute  Department for Bioscience at Novum Stockholm, Sweden 
67 Prof. Werner Lutz University of Würzburg Department of Toxicology Würzburg, Germany 
68 Prof. Matilde Marques Technical University of Lisbon Structural Chemistry Centre Lisbon, Portugal 
69 Dr. Debbie Marsden University of Leicester Cancer Biomarkers and Prevention Group Leicester, UK 
70 Dr. Francis L. Martin Lancaster University Biological Sciences Lancaster, UK 
71 Prof. Giuseppe Matullo Institute for Scientific Interchange Foundation Molecular Epidemiology Laboratory Torino, Italy 
72 Ms. Mayura Meerang German Cancer Research Center Division of Toxicology and Cancer Risk Factors Heidelberg, Germany 
73 Dr. Christopher Michejda National Cancer Institute at Frederick Molecular Aspects of Drug Design Frederick, MD, USA 
74 Prof. Lennart Möller Karolinska Institute  Department for Bioscience at Novum   Stockholm, Sweden
75 Dr. Karsten Müller BASF AG GUP/CB, Z470 Ludwigshafen, Germany 
List of Participants 
 52
76 Dr. Jagadeesan Nair German Cancer Research Center Division of Toxicology and Cancer Risk Factors Heidelberg, Germany 
77 Dr. Urmila Nair German Cancer Research Center Division of Toxicology and Cancer Risk Factors Heidelberg, Germany 
78 Ms. Eszter Nagy Karolinska Institute  Department for Bioscience at Novum   Stockholm, Sweden
79 Mrs. Zuzana Novakova Academy of Sciences of the Czech Republic Institute of Experimental Medicine Prague, Czech Republic 
80 Prof. Barrbara Oesch University of Mainz Institute of Toxicology  
81 Prof. Franz Oesch University of Mainz Institute of Toxicology  
82 Dr. Marco Peluso Tuscany Cancer Institute Molecular Biology Laboratory Florence, Italy 
83 Prof. Wolfgang Pfau GAB-Consulting Toxicology Lamstedt, Germany 
84 Prof. Annie Pfohl-Leszkowicz ENSAT Laboratoire de Génie Chimique Auzeville-Tolosane, France 
85 Prof. David Phillips Institute of Cancer Research Section of Molecular Carcinogenesis Sutton, UK 
86 Dr. Cecilia Diaz Pohl AstraZeneca R&D Södertälje Department of Genetic and Cellular Toxicology Södertälje, Sweden 
87 Ms. Nektaria Polychronaki University of Kuopio Department of Public Health and Clinical Nutrition Kuopio, Finland 
88 Dr. Andrew Povey University of Manchester Centre for Occupational and Environmental Health Manchester, UK 
89 Prof. Rudolf Preussmann  Goethestr. 50 Eppelheim, Germany 
90 Prof. Elmar Richter Ludwig-Maximilian University of Munich Walter-Straub Institute for Pharmacology and Toxicology Munich, Germany 
91 Dr. Sabine Rohrmann German Cancer Research Center Division of Clinical Epidemiology Heidelberg, Germany 
92 Dr. Michael Routledge University of Leeds Molecular Epidemiology Unit Leeds, UK 
93 Dr. Andreas Rothfuss Schering AG Department of Experimental Toxicology Berlin, Germany 
94 Dr. Rafal Rozalski Nicolaus Copernicus University Department of Clinical Biochemistry   Bydgoszcz, Poland
95 Prof. Gabriele Sabbioni Institute of Environmental and Occupational 
Toxicology 
 Airolo, Switzerland  
96 Ms. Tove Sandberg Karolinska Institute  Department for Bioscience at Novum Stockholm, Sweden 
97 Prof. Gerhard Scherer ABF Analytisch-Biologisches Forschungslabor 
GmbH 
 Munich, Germany  
98 PD. Dr. Heinz Schmeiser German Cancer Research Center Division of Molecular Toxicology Heidelberg, Germany 
99 PD. Dr. Oliver Schmitz University of Wuppertal Department of Analytical Chemistry Wuppertal, Germany 
100 Dr. Gisela Werle-Schneider German Cancer Research Center Division of Toxicology and Cancer Risk Factors Heidelberg, Germany 
101 Dr. Bernadette Schoket National Institute of Environmental Health Jozsef Fodor National Center for Public Health Budapest, Hungary 
102 Dr. Markus Schulz BASF AG GV/TB Z 470 Ludwigshafen, Germany 
103 Ms. Berta Schulz University of Würzburg Department of Toxicology Würzburg, Germany 
104 Dr. Dan Segerbäck Karolinska Institute  Department for Bioscience at Novum   Stockholm, Sweden
105 PD. Dr. Albrecht Seidel Prof Dr Gernot Grimmer-Foundation Biochemical Institute for Environmental Carcinogens Hamburg, Germany 
106 Dr. Hasan Seker Roche Diagnostics GmbH  Mannheim, Germany 
107 Ms. Oksana Sevastyanova Academy of Sciences of the Czech Republic Institute of Experimental Medicine  Prague, Czech Republic 
108 Dr. Raj Singh University of Leicester Cancer Biomarkers and Prevention Group Leicester, UK 
109 Ms. Agnieszka Siomek Nicolaus Copernicus University Department of Clinical Biochemistry   Bydgoszcz, Poland
110 Dr. Renate Slacik-Erben Altana Pharma AG Department of Genetic Toxicology Barsbüttel, Germany 
111 Ms. Yasmin Sommer German Institute for Human Nutrition Department of Toxicology Berlin, Germany 
112 Dr. Vassilis Souliotis National Hellenic Research Foundation Institute of Biological Research and Biotechnology Athens, Greece 
113 Mr. Bülent Soyalan Technical University of Kaiserslautern Division of Food Chemistry & Environmental Toxicology Kaiserslautern, Germany 
List of Participants 
 53
List of Participants 
114 Mr. Thomas Spormann Technical University of Kaiserslautern Division of Food Chemistry & Environmental Toxicology Kaiserslautern, Germany 
115 Dr. Dirk Stach German Cancer Research Center Division of Epigenetics Heidelberg, Germany 
116 Dr. Thomas Steger-Hartmann Schering AG Department of Experimental Toxicology Berlin, Germany 
117 Prof. Marie Stiborova Charles University Department of Biochemistry Prague, Czech Republic 
118 Mrs. Silke Thielen Technical University of Kaiserslautern Division of Food Chemistry & Environmental Toxicology Kaiserslautern, Germany 
119 Mr. Markus Thiemann University of Wuppertal Department of Analytical Chemistry Wuppertal, Germany 
120 Dr. Jan Topinka Institute of Experimental Medicine AS CR Laboratory of Genetic Ecotoxicology Prague, Czech Republic 
121 Dr. Anthony Tricker Philip Morris Products S.A.  Neuchatel, Switzerland 
122 Prof. Federik-Jan van Schooten University of Maastricht Department of Health Risk Analysis and Toxicology Maastricht, The Netherlands 
123 Ms. Nicole Verhofstad University of Maastricht Department of Health Risk Analysis and Toxicology Maastricht, The Netherlands 
124 Mr. Jochen von Brocke German Cancer Research Center Division of Molecular Toxicology Heidelberg, Germany 
125 Mr. Paul Wanek University of Würzburg Department of Toxicology Würzburg, Germany 
126 Prof. Manfred Wiessler German Cancer Research Center Division of Molecular Toxicology Heidelberg, Germany 
127 Dr. Olaf Will Grünenthal GmbH  Aachen, Germany 
128 Dr. Uta Wirnitzer Bayer HealthCare AG Department of Toxicology Wuppertal, Germany 
129 Dr. Hans-Eric Wollny RCC Cytotest Cell Research GmbH  Rossdorf, Germany 
130 Mr. Jie Zuo Institute of Cancer Research Section of Molecular Carcinogenesis Sutton, UK 
 
